Clinical trial results:
A Phase Ib, Randomized, Observer-Blind, Multicenter, Factorial-Design Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Injections of Trivalent Inactivated Influenza Vaccine with or without a Second Influenza B Strain in Combination with or without One of Three Different Doses of Adjuvant in Healthy Children, Ages 6 to <36 Months.

Summary

EudraCT number	2008-002602-20
Trial protocol	FI BE
Global end of trial date	30 March 2009

Results information

Result version number	v2 (current)
This version publication date	29 July 2016
First version publication date	12 April 2015
Version creation reason	• Correction of full data set Required for the re-QC project because of the EudraCT system glitch and possible updates to results may be required. Moreover, a change in system user for this study is necessary.

Trial information

Trial identification

Sponsor protocol code	V104P2

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00848887
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Vaccines and Diagnostics S.r.l.
Sponsor organisation address	Via Fiorentina, 1, Siena, Italy, 53100
Public contact	Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com
Scientific contact	Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 November 2010
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	30 March 2009
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To Evaluate:
A.Noninferiority of study vaccine to the pediatric trivalent influenza vaccine (TIV) formulated with MF59 at ½ dose of the marketed adult adjuvanted vaccine, Fluad
B.Superiority of study vaccine to TIV formulated with ½MF59 Fluad
C.Superiority of study vaccine formulation to non adjuvanted pediatric marketed comparator Vaxiprip (cTIV)
D.Similarity of antibody response to single vaccination for any formulation to two 0.25mL vaccination of an aTIV/aQIV+½MF59 & TIV/QIV+0MF59
E.Increase in antibody responses of B strain (Malaysia) (B_MY) on addition of B_MY to TIV/QIV
F.Increase in cross-reactive antibody responses to A/H3N2, A/H1N1 and B strain(Florida) (B-FL) on addition of B_MY to TIV/QIV
G.Increase in cross-reactive antibody responses to B_MY on increase in antigen dose in TIV
H.Immunogenicity of study vaccine formulations according to the EMEA recommendation
I.MF59 dose-response trend in antibody responses
J.Safety and tolerability of study vaccine formulations

Protection of trial subjects:

This trial was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with Good Clinical Practice (GCP), and the applicable regulatory requirement(s) for the country in which the trial was conducted according to International Conference on Harmonisation (ICH) guidelines, and applicable Standard Operating Procedures (SOPs).

Background therapy:

NA

Evidence for comparator:

NA

Actual start date of recruitment	17 October 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 208
Country: Number of subjects enrolled	Finland: 202
Worldwide total number of subjects	410
EEA total number of subjects	410

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	304
Children (2-11 years)	106
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled from two study center.

Pre-assignment

Screening details:

All enrolled subjects were included in the trial.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	A_7.5TIV+0MF59

Arm description:

Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Active comparator
Investigational medicinal product name	Nonadjuvanted Trivalent influenza vaccine(TIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL of TIV was administered by IM injection.

Arm title	B_15TIV+0MF59

Arm description:

Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 15µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	Nonadjuvanted Trivalent influenza vaccine(TIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL dose of TIV was administered by IM injection.

Arm title	C_7.5QIV+0MF59

Arm description:

Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Experimental

Investigational medicinal product name	Nonadjuvanted Quadravalent influenza vaccine(QIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of TIV was administered by IM injection.

Arm title	D_15QIV+0MF59

Arm description:

Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 15µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	Nonadjuvanted Quadravalent influenza vaccine(QIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL dose of TIV was administered by IM injection.

Arm title	Q_7.5cTIV+0MF59

Arm description:

Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (cTIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Active comparator
Investigational medicinal product name	Nonadjuvanted Trivalent influenza vaccine(cTIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of TIV was administered by IM injection.

Arm title	E_7.5aTIV+⅛MF59

Arm description:

Subjects who received 2 doses of ⅛ MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Trivalent influenza vaccine (aTIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of TIV was administered by IM injection.

Arm title	F_7.5aQIV+⅛MF59

Arm description:

Subjects who received 2 doses of ⅛MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Experimental

Investigational medicinal product name	adjuvanted Quadravalent influenza vaccine (aQIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of TIV was administered by IM injection.

Arm title	G_7.5aTIV+¼MF59

Arm description:

Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Trivalent influenza vaccine (aTIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of TIV was administered by IM injection.

Arm title	H_15aTIV+¼MF59

Arm description:

Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Trivalent influenza vaccine (aTIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL dose of aTIV was administered by IM injection.

Arm title	I_7.5aQIV+¼MF59

Arm description:

Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV – 7.5µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Quadravalent influenza vaccine (aQIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of aQIV was administered by IM injection.

Arm title	J_15aQIV+¼MF59

Arm description:

Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.

Arm type	Experimental

Investigational medicinal product name	adjuvanted Quadravalent influenza vaccine (aQIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL dose of TIV was administered by IM injection.

Arm title	K_7.5aTIV+½MF59

Arm description:

Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Trivalent Influenza Vaccine (aTIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of TIV was administered by IM injection.

Arm title	L_15aTIV+½MF59

Arm description:

Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Trivalent Influenza Vaccine (aTIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL dose of aTIV was administered by IM injection.

Arm title	M_7.5aQIV+½MF59

Arm description:

Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Quadravalent Influenza Vaccine (aQIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.25 mL dose of aQIV was administered by IM injection.

Arm title	N_15aQIV+½MF59

Arm description:

Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.

Arm type	Experimental

Investigational medicinal product name	adjuvanted Quadravalent Influenza Vaccine (aQIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL dose of TIV was administered by IM injection.

Arm title	O_15aTIV+fullMF59

Arm description:

Subjects who received one dose of full MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Trivalent Influenza Vaccine (aTIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of 0.5 mL dose of TIV was administered by IM injection.

Arm title	P_15aQIV+fullMF59

Arm description:

Subjects who received one dose of full MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1.

Arm type	Experimental
Investigational medicinal product name	adjuvanted Quadravalent Influenza Vaccine (aQIV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of 0.5 mL dose of aQIV was administered by IM injection.

Number of subjects in period 1	A_7.5TIV+0MF59	B_15TIV+0MF59	C_7.5QIV+0MF59
Started	25	22	25
Completed	24	22	24
Not completed	1	0	1
Consent withdrawn by subject	-	-	1
Adverse Events	-	-	-
Lost to follow-up	-	-	-
Unable to Classify	1	-	-

Number of subjects in period 1	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Started	28	26	24
Completed	25	26	24
Not completed	3	0	0
Consent withdrawn by subject	2	-	-

Adverse Events	1	-	-
Lost to follow-up	-	-	-
Unable to Classify	-	-	-

Number of subjects in period 1	F_7.5aQIV+⅛MF59	G_7.5aTIV+¼MF59	H_15aTIV+¼MF59
Started	23	23	21
Completed	21	22	19
Not completed	2	1	2
Consent withdrawn by subject	2	-	2
Adverse Events	-	-	-
Lost to follow-up	-	1	-
Unable to Classify	-	-	-

Number of subjects in period 1	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	K_7.5aTIV+½MF59
Started	24	24	27
Completed	22	24	27
Not completed	2	0	0
Consent withdrawn by subject	1	-	-
Adverse Events	-	-	-
Lost to follow-up	1	-	-
Unable to Classify	-	-	-

Number of subjects in period 1	L_15aTIV+½MF59	M_7.5aQIV+½MF59	N_15aQIV+½MF59
Started	23	22	25
Completed	22	22	25
Not completed	1	0	0
Consent withdrawn by subject	1	-	-
Adverse Events	-	-	-
Lost to follow-up	-	-	-
Unable to Classify	-	-	-

Number of subjects in period 1	O_15aTIV+fullMF59	P_15aQIV+fullMF59
Started	26	22
Completed	24	22
Not completed	2	0
Consent withdrawn by subject	1	-
Adverse Events	-	-
Lost to follow-up	1	-
Unable to Classify	-	-

Reporting groups	
Reporting group title	A_7.5TIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	B_15TIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	C_7.5QIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	D_15QIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	Q_7.5cTIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (cTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	E_7.5aTIV+⅛MF59
Reporting group description:	
Subjects who received 2 doses of ⅛ MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	F_7.5aQIV+⅛MF59
Reporting group description:	
Subjects who received 2 doses of ⅛MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	G_7.5aTIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	H_15aTIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	I_7.5aQIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV – 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	J_15aQIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	K_7.5aTIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	L_15aTIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.	

Reporting group title	M_7.5aQIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	N_15aQIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	O_15aTIV+fullMF59
Reporting group description:	
Subjects who received one dose of full MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1.	
Reporting group title	P_15aQIV+fullMF59
Reporting group description:	
Subjects who received one dose of full MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1.	

Reporting group values	A_7.5TIV+0MF59	B_15TIV+0MF59	C_7.5QIV+0MF59
Number of subjects	25	22	25
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	16	18	17
Children (2-11 years)	9	4	8
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: months			
arithmetic mean	20	15	18
standard deviation	± 7	± 8.8	± 8.9
Gender categorical Units: Subjects			
Female	14	6	9
Male	11	16	16

Reporting group values	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Number of subjects	28	26	24
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	23	20	15
Children (2-11 years)	5	6	9

Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: months			
arithmetic mean	15.2	16.1	18.5
standard deviation	± 7.8	± 8.5	± 9.3
Gender categorical			
Units: Subjects			
Female	13	13	11
Male	15	13	13

Reporting group values	F_7.5aQIV+⅛MF59	G_7.5aTIV+¼MF59	H_15aTIV+¼MF59
Number of subjects	23	23	21
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	15	17	17
Children (2-11 years)	8	6	4
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: months			
arithmetic mean	17	16.4	15.4
standard deviation	± 9	± 7.4	± 7.6
Gender categorical			
Units: Subjects			
Female	14	13	13
Male	9	10	8

Reporting group values	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	K_7.5aTIV+½MF59
Number of subjects	24	24	27
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	18	19	18
Children (2-11 years)	6	5	9
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0

Age continuous			
Units: months			
arithmetic mean	16.6	16	19
standard deviation	± 8.8	± 9.4	± 9.4
Gender categorical			
Units: Subjects			
Female	13	12	11
Male	11	12	16

Reporting group values	L_15aTIV+½MF59	M_7.5aQIV+½MF59	N_15aQIV+½MF59
Number of subjects	23	22	25
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	17	16	20
Children (2-11 years)	6	6	5
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: months			
arithmetic mean	18.3	16.3	15.4
standard deviation	± 8.7	± 9	± 9.2
Gender categorical			
Units: Subjects			
Female	15	13	12
Male	8	9	13

Reporting group values	O_15aTIV+fullMF59	P_15aQIV+fullMF59	Total
Number of subjects	26	22	410
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	23	15	304
Children (2-11 years)	3	7	106
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: months			
arithmetic mean	14.2	17.8	
standard deviation	± 7.1	± 8.7	-

Gender categorical Units: Subjects			
Female	15	6	203
Male	11	16	207

End points

End points reporting groups

Reporting group title	A_7.5TIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	B_15TIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	C_7.5QIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	D_15QIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	Q_7.5cTIV+0MF59
Reporting group description:	
Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (cTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	E_7.5aTIV+⅛MF59
Reporting group description:	
Subjects who received 2 doses of ⅛ MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	F_7.5aQIV+⅛MF59
Reporting group description:	
Subjects who received 2 doses of ⅛MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	G_7.5aTIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	H_15aTIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	I_7.5aQIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV – 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	J_15aQIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	K_7.5aTIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	L_15aTIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.	

Reporting group title	M_7.5aQIV+½MF59

Reporting group description:

Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.

Reporting group title	N_15aQIV+½MF59

Reporting group description:

Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.

Reporting group title	O_15aTIV+fullMF59

Reporting group description:

Subjects who received one dose of full MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1.

Reporting group title	P_15aQIV+fullMF59

Reporting group description:

Subjects who received one dose of full MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1.

Subject analysis set title	All enrolled population
Subject analysis set type	Intention-to-treat

Subject analysis set description:

All subjects who were enrolled in the study irrespective of whether or not they were randomized. An analysis of the "All Enrolled Population" was not planned.

Subject analysis set title	Per Protocol Set (PPS) (Visit-1) Day 1
Subject analysis set type	Per protocol

Subject analysis set description:

All enrolled subjects who received the vaccinations correctly, provided evaluable serum samples at the relevant time points (visit 1), and had no major protocol violation as defined prior to unblinding.
A major deviation was defined as a protocol deviation considered to have a significant impact on the immunogenicity result of the subject. In case of randomization errors, subjects were analyzed as treated in the PPS.

Subject analysis set title	Per Protocol Set (PPS) (Visit-3) Day 29
Subject analysis set type	Per protocol

Subject analysis set description:

All enrolled subjects who received the vaccinations correctly, provided evaluable serum samples at the relevant time points (Visit-3), and had no major protocol violation as defined prior to unblinding.
A major deviation was defined as a protocol deviation considered to have a significant impact on the immunogenicity result of the subject. In case of randomization errors, subjects were analyzed as treated in the PPS.

Subject analysis set title	Per Protocol Set (PPS) (Visit-5) Day 50
Subject analysis set type	Per protocol

Subject analysis set description:

All enrolled subjects who received the vaccinations correctly, provided evaluable serum samples at the relevant time points (Visit-5), and had no major protocol violation as defined prior to unblinding.
A major deviation was defined as a protocol deviation considered to have a significant impact on the immunogenicity result of the subject. In case of randomization errors, subjects were analyzed as treated in the PPS.

Subject analysis set title	Safety Set
Subject analysis set type	Safety analysis

Subject analysis set description:

All subjects enrolled who received at least one study vaccination and provided post-baseline safety data.

Subject analysis set title	A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in healthy subjects aged 6 to <36 months who received non adjuvanted trivalent/quadravalent influenza vaccine (TIV/QIV - 7.5µg per antigen).

Subject analysis set title	B_15TIV+0MF59 + D_15QIV+0MF59

Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in healthy subjects aged 6 to <36 months who received non adjuvanted trivalent /quadravalent influenza vaccine (TIV/QIV - 15µg per antigen).

Subject analysis set title	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in healthy subjects aged 6 to <36 months who received eighth MF59 dose adjuvanted trivalent/quadravalent influenza vaccine (aTIV/aQIV - 7.5µg per antigen).

Subject analysis set title	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in healthy subjects aged 6 to <36 months who received quarter MF59 dose adjuvanted trivalent/quadravalent influenza vaccine (aTIV/aQIV - 7.5µg per antigen).

Subject analysis set title	H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in healthy subjects aged 6 to <36 months who received quarter MF59 dose adjuvanted trivalent/quadravalent influenza vaccine (aTIV/aQIV - 15µg per antigen).

Subject analysis set title	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in healthy subjects aged 6 to <36 months who received half MF59 dose adjuvanted trivalent /quadravalent influenza vaccine (aTIV/aQIV - 7.5µg per antigen)

Subject analysis set title	A_7.5TIV+0MF59 + B_15TIV+0MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received non adjuvanted 7.5µg and 15 µg per antigen trivalent influenza vaccine (TIV) on day 1 and day 29.

Subject analysis set title	G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received quarter MF59 dose adjuvanted, 7.5µg and 15µg per antigen trivalent influenza vaccine(aTIV) on day 1 and day 29.

Subject analysis set title	K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received half MF59 dose adjuvanted, 7.5µg and 15µg per antigen trivalent influenza vaccine (aTIV) on day 1 and day 29.

Subject analysis set title	L_15aTIV+½MF59 + N_15aQIV+½MF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects received half MF59 Dose adjuvanted, 15µg per antigen trivalent/quadravalent influenza vaccine (aTIV/aQIV - 15µg per antigen) on day 1 and day 29.

Subject analysis set title	O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received full MF59 dose adjuvanted trivalent/quadravalent influenza vaccine (aTIV/aQIV - 15µg per antigen) on day 1 and day 29.

Subject analysis set title	AEGK
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received non adjuvanted/ eighth/ quarter/ half adjuvanted 7.5µg per antigen trivalent influenza vaccine (aTIV).
(A_7.5TIV+0MF59+ E_7.5aTIV+⅛MF59 + G_7.5aTIV+¼MF59 + K_7.5aTIV+½MF59)

Subject analysis set title	BHL

Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received non adjuvanted/ eighth/ quarter/ half adjuvanted 15 µg per antigen trivalent influenza vaccine (aTIV).
(B_15TIV+0MF59 + H_15aTIV+¼MF59 + L_15aTIV+½MF59)

Subject analysis set title	CFIM
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received non adjuvanted/ eighth/ quarter/ half adjuvanted 7.5µg per antigen quadravalent influenza vaccine (aTIV).
(C_7.5QIV+0MF59 + F_7.5aQIV+⅛MF59 + I_7.5aQIV+¼MF59 + M_7.5aQIV+½MF59)

Subject analysis set title	DJN
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received non adjuvanted/ eighth/ quarter/ half adjuvanted 15µg per antigen quadravalent influenza vaccine (aTIV).
(D_15QIV+0MF59 + J_15aQIV+¼MF59 + N_15aQIV+½MF59)

Subject analysis set title	AGK
Subject analysis set type	Per protocol

Subject analysis set description:

Study vaccine combinations in subjects who received non adjuvanted/ quarter/ half adjuvanted 7.5µg per antigen trivalent influenza vaccine (TIV/aTIV) on day 1 and day 29.
(A_7.5TIV+0MF59 + G_7.5aTIV+¼MF59 + K_7.5aTIV+½MF59)

Subject analysis set title	Slope (log10) inc. 95% CI
Subject analysis set type	Per protocol

Subject analysis set description:

Dose-response relationship for MF59 using a linear regression analysis with dose and day 50 antibody titers to log base 10.

Subject analysis set title	Slope incl. 95% CI
Subject analysis set type	Per protocol

Subject analysis set description:

Dose-response relationship for MF59 using a linear regression analysis with dose and day 50 antibody titers.

Primary: 1. To assess non-inferiority of study vaccine formulations to the pediatric trivalent influenza vaccine (TIV - 7.5µg per antigen) formulated with MF59 at half the dose of the marketed adult adjuvanted vaccine.

End point title	1. To assess non-inferiority of study vaccine formulations to the pediatric trivalent influenza vaccine (TIV - 7.5µg per antigen) formulated with MF59 at half the dose of the marketed adult adjuvanted vaccine.

End point description:

To assess immunogenicity in terms of Geometric Mean Titer (GMT) in order to evaluate whether any of the study vaccine formulations is noninferior to the pediatric trivalent influenza vaccine (TIV - 7.5µg per antigen) formulated with MF59 at half the dose of the marketed adult adjuvanted vaccine, Fluad for three strains.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

End point values	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	49	49	44	44
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	6.4 (4.7 to 8.72)	6.54 (4.8 to 8.91)	8.15 (5.88 to 11)	8.41 (6.07 to 12)
A/H1N1 (Day 29) (N=37,43,37,35,33,41)	14 (7.76 to 24)	12 (7.2 to 21)	109 (62 to 193)	118 (65 to 212)
A/H1N1 (Day 50) (N= 37,42,36,34,33,40)	57 (37 to 85)	69 (47 to 102)	533 (351 to 810)	481 (313 to 740)
A/H3N2 (Day1)	7.38 (5.22 to 10)	7.22 (5.11 to 10)	7.96 (5.53 to 11)	9.54 (6.62 to 14)
A/H3N2 (Day 29) (N=37,43,37,35,33,41)	19 (12 to 30)	12 (7.52 to 18)	91 (57 to 145)	114 (71 to 184)
A/H3N2 (Day 50) (N= 37,42,36,34,33,40)	73 (50 to 106)	60 (42 to 86)	518 (354 to 758)	496 (335 to 734)
B_FL (Day 1)	5.37 (4.8 to 6)	5.29 (4.73 to 5.92)	6.23 (5.54 to 7.02)	6.33 (5.63 to 7.13)
B_FL (Day 29) (N=37,43,37,35,33,41)	8.45 (5.64 to 13)	6.74 (4.63 to 9.8)	9.37 (6.26 to 14)	13 (8.29 to 19)
B_FL (Day 50) (N= 37,42,36,34,33,40)	13 (9.45 to 18)	11 (7.98 to 15)	61 (43 to 84)	61 (43 to 86)

End point values	H_15aTIV+¼MF59 + J_15aQIV+¼MF59	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	44	49		
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	7.83 (5.66 to 11)	7.7 (5.65 to 10)		
A/H1N1 (Day 29) (N=37,43,37,35,33,41)	149 (81 to 272)	118 (69 to 203)		
A/H1N1 (Day 50) (N= 37,42,36,34,33,40)	576 (372 to 892)	529 (356 to 787)		
A/H3N2 (Day1)	6.8 (4.72 to 9.79)	8.44 (5.97 to 12)		
A/H3N2 (Day 29) (N=37,43,37,35,33,41)	112 (68 to 183)	150 (96 to 232)		
A/H3N2 (Day 50) (N= 37,42,36,34,33,40)	503 (338 to 748)	608 (423 to 872)		
B_FL (Day 1)	5.16 (4.58 to 5.81)	5.8 (5.18 to 6.49)		
B_FL (Day 29) (N=37,43,37,35,33,41)	8.45 (5.51 to 13)	9.59 (6.53 to 14)		
B_FL (Day 50) (N= 37,42,36,34,33,40)	69 (49 to 98)	81 (59 to 112)		

Statistical analyses

Statistical analysis title	A/H1N1: Day 1 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5 aTIV+½MF59 + M_7.5 aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[1]
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.08

Notes:

[1] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 1 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg /antigen TIV and QIV, adjuvanted with ½MF59 dose for strain A/H1N1 on day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5 aTIV+½MF59 + M_7.5 aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[2]
P-value	= 0.14
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.32

Notes:

[2] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 1 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[3]
P-value	= 0.023
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.66

Notes:

[3] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 1 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.016
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.71

Statistical analysis title	A/H1N1: Day 1 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.034
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.59

Statistical analysis title	A/H1N1: Day 29 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg /antigen aTIV and aQIV, adjuvanted with ½MF59 dose for strain A/H1N1 on Day 29.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.053
upper limit	0.26

Statistical analysis title	A/H1N1: Day 29 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½MF59 dose for strain A/H1N1 on day 29.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.049
upper limit	0.22

Statistical analysis title	A/H1N1: Day 29 (EF:KM)
Statistical analysis description:	
Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 29. (E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)	
Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.21
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.42
upper limit	2.03

Statistical analysis title	A/H1N1: Day 29 (GI:KM)
Statistical analysis description:	
Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 29. (G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)	
Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	2.22

Statistical analysis title	A/H1N1: Day 29 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 29.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[4]
P-value	= 0.064
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	2.84

Notes:

[4] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 50 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF593)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[5]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.19

Notes:

[5] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 50 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza

vaccine, to that of 7.5µg /antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[6]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.075
upper limit	0.23

Notes:

[6] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 50 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H1N1 on day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.082 [7]
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	1.79

Notes:

[7] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 50 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/ antigen TIV and QIV influenza vaccine, adjuvanted with ¼MF59 dose influenza vaccines to that of 7.5µg/ antigen TIV and QIV, adjuvanted with ½MF59 dose for strain A/H1N1 on Day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[8]
P-value	= 0.15
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.63

Notes:

[8] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 50 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/antigen TIV and QIV influenza vaccine, adjuvanted with ¼MF59 dose influenza vaccines to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½MF59 dose for strain A/H1N1 on Day 50.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[9]
P-value	= 0.053
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.97

Notes:

[9] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2: Day 1 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½MF59 dose for strain A/H3N2 on day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5 aTIV+½MF59 + M_7.5 aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[10]
P-value	= 0.14
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.87

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.42

Notes:

[10] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[11]
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.4

Notes:

[11] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[12]
P-value	= 0.091
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	1.56

Notes:

[12] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[13]
P-value	= 0.021
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.87

Notes:

[13] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[14]
P-value	= 0.024
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.33

Notes:

[14] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza

vaccine, to that of 7.5µg /antigen aTIV and aQIV, adjuvanted with ½MF59 dose for strain A/H3N2 on day 29.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[15]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.065
upper limit	0.24

Notes:

[15] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 29.
(B_15 TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[16]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.077
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.042
upper limit	0.14

Notes:

[16] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 29.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[17]
P-value	= 0.61
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	1.16

Notes:

[17] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2: Day 29 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 29.
(G_7.5 aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5 aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[18]
P-value	= 0.35
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	1.46

Notes:

[18] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2: Day 29 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/ antigen TIV and QIV influenza vaccine, adjuvanted with ¼MF59 dose influenza vaccines to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½MF59 dose for strain A/H3N2 on day 29.
(H_15aTIV+¼MF59+ J_15aQIV+¼MF59 : K_7.5aTIV+½MF591+ M_7.5aQIV+½MF593)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[19]
P-value	= 0.37
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.75

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	1.45

Notes:

[19] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 50 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[20]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.071
upper limit	0.2

Notes:

[20] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 50 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½MF59 dose for strain A/H3N2 on day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF593)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[21]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.099
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.16

Notes:

[21] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 50 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen TIV and QIV influenza vaccine, adjuvanted with ⅛MF59 dose influenza vaccines to that of 7.5µg / antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF591+ M_7.5aQIV+½MF593)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.18
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.44

Statistical analysis title	A/H3N2: Day 50 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain A/H3N2 on day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5 aTIV+½MF591 + M_7.5 aQIV+½MF593)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.23
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	1.39

Statistical analysis title	A/H3N2: Day 50 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/ antigen TIV and QIV influenza vaccine,

adjuvanted with ¼MF59 dose influenza vaccines to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½MF59 dose for strain A/H3N2 on day 50.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF591 + M_7.5aQIV+½MF593)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[22]
P-value	= 0.22
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	1.42

Notes:

[22] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½MF59 dose for strain B_FL on day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[23]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.29

Notes:

[23] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½MF59 dose for strain B_FL on day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[24]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.07

Notes:

[24] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL: Day 1 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛ MF59 dose influenza vaccines to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½ MF59 dose for strain B_FL on day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[25]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.91
upper limit	1.27

Notes:

[25] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL: Day 1 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½MF59 dose for strain B_FL on day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	1.29

Statistical analysis title	B_FL: Day 1 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.05

Statistical analysis title	B_FL: Day 29 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 29.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[26]
P-value	= 0.17
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.54

Notes:

[26] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 29.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[27]
P-value	= 0.43
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	1.2

Notes:

[27] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 29.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[28]
P-value	= 0.092
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.7

Notes:

[28] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine,

adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 29.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.01
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	2.3

Statistical analysis title	B_FL: Day 29 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 29.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.17
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.57

Statistical analysis title	B_FL: Day 50 (AC:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of non adjuvanted 7.5µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[29]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.1
upper limit	0.25

Notes:

[29] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL: Day 50 (BD:KM)

Statistical analysis description:

Non-inferioriority of study vaccine combinations of non adjuvanted 15µg/antigen TIV and QIV influenza vaccine, to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[30]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.086
upper limit	0.21

Notes:

[30] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL: Day 50 (EF:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ⅛ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½ MF59 dose for strain B_FL on day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[31]
P-value	= 0.33
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.74

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.18

Notes:

[31] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 50 (GI:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg/antigen TIV and QIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen TIV and QIV, adjuvanted with ½ MF59 dose for strain B_FL on day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.32
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.19

Statistical analysis title	B_FL: Day 50 (HJ:KM)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 15µg/antigen aTIV and aQIV influenza vaccine, adjuvanted with ¼ MF59 dose influenza vaccines to that of 7.5µg/antigen aTIV and aQIV, adjuvanted with ½MF59 dose for strain B_FL on day 50.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.36

Primary: 2. To assess non-inferiority of 7.5 µg QIV formulated with half MF59 to 7.5µg and 15µg TIV and QIV groups.

End point title	2. To assess non-inferiority of 7.5 µg QIV formulated with half MF59 to 7.5µg and 15µg TIV and QIV groups.[32]

End point description:

To assess non-inferiority of the 7.5 µg aQIV formulated with half MF59 in terms of GMTs, the 7.5µg and 15µg TIV groups of the same adjuvant concentration were combined, while the QIV groups for the second B-strain, B_Malaysia (B_MY).
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	E_7.5aTIV+⅛MF59	F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	28	23	21
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY(Day1)	5 (4.86 to 5.14)	5 (4.87 to 5.13)	5 (4.86 to 5.14)	5.17 (5.02 to 5.32)
B_MY(Day 29)	6.39 (5.24 to 7.79)	5 (4.2 to 5.95)	6.22 (5.16 to 7.51)	6.06 (5 to 7.35)
B_MY(Day50)	11 (7.12 to 16)	9.68 (6.58 to 14)	10 (6.85 to 16)	42 (28 to 64)

End point values	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59	A_7.5TIV+0MF59 + B_15TIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	22	24	22	46
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY(Day1)	5 (4.86 to 5.15)	5.15 (5.01 to 5.29)	5 (4.86 to 5.15)	5 (4.9 to 5.1)
B_MY(Day 29)	5.83 (4.81 to 7.07)	6.55 (5.4 to 7.94)	6.22 (5.16 to 7.51)	5 (4.39 to 5.69)
B_MY(Day50)	63 (42 to 96)	63 (41 to 96)	70 (47 to 106)	5.74 (4.34 to 7.6)

End point values	G_7.5aTIV+¼ MF59 + H_15aTIV+¼M F59	K_7.5aTIV+½ MF59 + L_15aTIV+½M F59		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	42	47		
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY(Day1)	5 (4.9 to 5.11)	5.07 (4.97 to 5.18)		
B_MY(Day 29)	5.45 (4.72 to 6.3)	5.79 (5.07 to 6.61)		
B_MY(Day50)	11 (8.33 to 16)	14 (11 to 19)		

Statistical analyses

Statistical analysis title	B_MY:Day 1 (AB:M)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg and 15µg/antigen non-adjuvanted TIV to that of 7.5µg/antigen QIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1. (A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF593)

Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	non-inferiority[33]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.04

Notes:

[33] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (C:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen non-adjuvanted QIV to that of 7.5µg/antigen QIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1. (C_7.5QIV+0MF59 : M_7.5aQIV+½MF593)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[34]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[34] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (D:M)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/ antigen non-adjuvanted QIV to that of 7.5µg/antigen QIV, adjuvanted with ½MF59 dose for strain B/Malaysia (B_MY) on day 1.
(D_15 QIV+0MF59 : M_7.5 aQIV+½MF593)

Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	non-inferiority[35]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[35] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (E:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aTIV, adjuvanted with ⅛ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1.
(E_7.5aTIV+⅛MF59 : M_7.5 aQIV+½MF593)

Comparison groups	E_7.5aTIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[36]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[36] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (F:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aQIV, adjuvanted with ⅛ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1.
(F_7.5aQIV+⅛MF59 : M_7.5aQIV+½MF593)

Comparison groups	F_7.5aQIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	non-inferiority[37]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[37] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY:Day 1 (GH:M)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg and 15µg/ antigen adjuvanted ¼ MF59 dose aTIV and aQIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1.
(G_7.5 aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF593)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	non-inferiority[38]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[38] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (I:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aQIV, adjuvanted with ¼ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF593)

Comparison groups	I_7.5aQIV+¼MF59 v M_7.5aQIV+½MF59

Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	non-inferiority[39]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[39] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (J:M)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen AQIV, adjuvanted with ¼ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1. (J_15aQIV+¼MF59 : M_7.5aQIV+½MF593)

Comparison groups	J_15aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[40]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.07

Notes:

[40] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY:Day 1 (KL:M)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg and 15µg/antigen adjuvanted ½ MF59 dose aTIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 1. (K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : M_7.5aQIV+½MF593)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	non-inferiority[41]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.05

Notes:

[41] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY:Day 29 (AB:M)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg and 15µg/antigen non-adjuvanted TIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29. (A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	non-inferiority[42]
P-value	= 0.059
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	1.01

Notes:

[42] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29 (C:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen non-adjuvanted QIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29. (C_7.5QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[43]
P-value	= 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.35

Notes:

[43] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY:Day 29 (D:M)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen non-adjuvanted QIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29.
(D_15QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	non-inferiority[44]
P-value	= 0.082
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.62
upper limit	1.04

Notes:

[44] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29 (E:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aTIV, adjuvanted with ⅛ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29.
(E_7.5aTIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[45]
P-value	= 0.002
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.3

Notes:

[45] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29 (F:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aQIV, adjuvanted with ⅛ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29.
(F_7.5aQIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v M_7.5aQIV+½MF59

Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	non-inferiority[46]
P-value	= 0.003
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.27

Notes:

[46] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29 (GH:M)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg and 15µg/antigen adjuvanted ¼ MF59 dose aTIV and aQIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF593)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	non-inferiority[47]
P-value	= 0.013
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.11

Notes:

[47] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY:Day 29 (I:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aQIV, adjuvanted with ¼ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	I_7.5aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	non-inferiority[48]
P-value	= 0.007
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.94

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.72
upper limit	1.23

Notes:

[48] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29 (J:M)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen aQIV, adjuvanted with ¼ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29. (J_15aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v J_15aQIV+¼MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[49]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	1.38

Notes:

[49] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29 (KL:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aQIV, adjuvanted with ¼ MF59 dose to that of 15µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 29. (K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	non-inferiority[50]
P-value	< 0.003
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.17

Notes:

[50] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 50 (AB:M)
Statistical analysis description:	
Non-inferiority of study vaccine combinations of 7.5µg and 15µg/antigen non-adjuvanted aTIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50. (A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF59)	
Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	non-inferiority[51]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.082
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.05
upper limit	0.13

Notes:

[51] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY:Day 50 (C:M)
Statistical analysis description:	
Non-inferiority of study vaccine of 7.5µg/antigen non-adjuvanted QIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50. (C_7.5QIV+0MF59 : M_7.5aQIV+½MF59)	
Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[52]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.086
upper limit	0.27

Notes:

[52] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 50 (D:M)
Statistical analysis description:	
Non-inferiority of study vaccine of 15µg/antigen non-adjuvanted QIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50. (D_15 QIV + 0MF59 : M_7.5 aQIV+ ½MF59)	
Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59

Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	non-inferiority[53]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.079
upper limit	0.24

Notes:

[53] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 50 (E:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aTIV, adjuvanted with ⅛ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50. (E_7.5TIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[54]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.083
upper limit	0.26

Notes:

[54] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 50 (F:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen QIV, adjuvanted with ⅛MF59 dose to that of 7.5µg/antigen QIV, adjuvanted with ½MF59 dose for strain B/Malaysia (B_MY) on day 50. (F_7.5QIV+⅛MF59 : M_7.5aQIV+½MF593)

Comparison groups	F_7.5aQIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	non-inferiority[55]
P-value	= 0.64
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	1.08

Notes:

[55] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 50 (GH:M)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg and 15µg/antigen adjuvanted ¼ MF59 dose aTIV and aQIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	non-inferiority[56]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.097
upper limit	0.27

Notes:

[56] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 50 (I:M)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen aQIV, adjuvanted with ¼ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	I_7.5aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	non-inferiority[57]
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.61

Notes:

[57] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 50 (J:M)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen aQIV, adjuvanted with ¼ MF59 dose to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50. (J_15aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	J_15aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[58]
P-value	= 0.17
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.61

Notes:

[58] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 50 (KL:M)

Statistical analysis description:

Non-inferiority of study vaccine combinations of 7.5µg and 15µg/antigen adjuvanted ½ MF59 dose aTIV to that of 7.5µg/antigen aQIV, adjuvanted with ½ MF59 dose for strain B/Malaysia (B_MY) on day 50. (K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	non-inferiority[59]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.12
upper limit	0.33

Notes:

[59] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Primary: 3. To evaluate superiority of any of the study vaccine formulations to the pediatric trivalent influenza vaccine (TIV - 7.5µg per antigen) formulated with MF59 at half the dose of the marketed adult adjuvanted vaccine, Fluad.

End point title	3. To evaluate superiority of any of the study vaccine formulations to the pediatric trivalent influenza vaccine (TIV - 7.5µg per antigen) formulated with MF59 at half the dose of the marketed adult adjuvanted vaccine, Fluad.

End point description:

To assess immunogenicity in terms of GMT in order to evaluate whether any of the study vaccine formulations is superior to the pediatric trivalent influenza vaccine (TIV - 7.5µg per antigen) formulated

with MF59 at half the dose of the marketed adult adjuvanted vaccine, Fluad.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

End point values	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	49	49	44	44
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	6.4 (4.7 to 8.72)	6.54 (4.8 to 8.91)	8.15 (5.88 to 11)	8.41 (6.07 to 12)
A/H1N1 (Day 29) (N=37,43,37,35,33,37,41)	14 (7.76 to 24)	12 (7.2 to 21)	109 (62 to 193)	118 (65 to 212)
A/H1N1 (Day 50) (N=37,42,36,34,33,36,40)	57 (37 to 85)	69 (47 to 102)	533 (351 to 810)	481 (313 to 740)
A/H3N2 (Day 1)	7.38 (5.22 to 10)	7.22 (5.11 to 10)	7.96 (5.53 to 11)	9.54 (6.62 to 14)
A/H3N2 (Day 29) (N=37,43,37,35,33,37,41)	19 (12 to 30)	12 (7.52 to 18)	91 (57 to 145)	118 (65 to 212)
A/H3N2 (Day 50) (N=37,42,36,34,33,36,40)	73 (50 to 106)	60 (42 to 86)	518 (354 to 758)	496 (335 to 734)
B_FL (Day 1)	5.37 (4.8 to 6)	5.29 (4.73 to 5.92)	6.23 (5.54 to 7.02)	6.33 (5.63 to 7.13)
B_FL (Day 29) (N=37,43,37,35,33,37,41)	8.45 (5.64 to 13)	6.74 (4.63 to 9.8)	9.37 (6.26 to 14)	13 (8.29 to 19)
B_FL (Day 50) (N=37,42,36,34,33,36,40)	13 (9.45 to 18)	11 (7.98 to 15)	61 (43 to 84)	61 (43 to 86)

End point values	H_15aTIV+¼MF59 + J_15aQIV+¼MF59	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59	L_15aTIV+½MF59 + N_15aQIV+½MF59	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	44	45	49	
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	7.83 (5.66 to 11)	7.7 (5.65 to 10)	7.58 (5.49 to 10)	
A/H1N1 (Day 29) (N=37,43,37,35,33,37,41)	149 (81 to 272)	118 (69 to 203)	220 (124 to 390)	
A/H1N1 (Day 50) (N=37,42,36,34,33,36,40)	576 (372 to 892)	529 (356 to 787)	718 (473 to 1092)	
A/H3N2 (Day 1)	6.8 (4.72 to 9.79)	8.44 (5.97 to 12)	6.6 (4.6 to 9.46)	
A/H3N2 (Day 29) (N=37,43,37,35,33,37,41)	112 (68 to 183)	150 (96 to 232)	163 (103 to 259)	

A/H3N2 (Day 50) (N=37,42,36,34,33,36,40)	503 (338 to 748)	608 (423 to 872)	559 (382 to 819)	
B_FL (Day 1)	5.16 (4.58 to 5.81)	5.8 (5.18 to 6.49)	5.48 (4.88 to 6.16)	
B_FL (Day 29) (N=37,43,37,35,33,37,41)	8.45 (5.51 to 13)	9.59 (6.53 to 14)	18 (12 to 27)	
B_FL (Day 50) (N=37,42,36,34,33,36,40)	69 (49 to 98)	81 (59 to 112)	101 (72 to 141)	

Statistical analyses

Statistical analysis title	A/H1N1: Day 1 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[60]
P-value	= 0.8
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.29

Notes:

[60] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5 TIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[61]
P-value	= 0.77
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.32

Notes:

[61] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[62]
P-value	= 0.4
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.66

Notes:

[62] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[63]
P-value	= 0.35
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.71

Notes:

[63] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[64]
P-value	= 0.47
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.59

Notes:

[64] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	L_15aTIV+½MF59 + N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[65]
P-value	= 0.53
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	1.54

Notes:

[65] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing

7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5 TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[66]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.053
upper limit	0.26

Notes:

[66] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[67]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.049
upper limit	0.22

Notes:

[67] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[68]
P-value	= 0.58
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.42
upper limit	2.03

Notes:

[68] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[69]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	2.22

Notes:

[69] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[70]
P-value	= 0.29
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.26

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	2.84

Notes:

[70] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	L_15aTIV+½MF59 + N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[71]
P-value	= 0.061
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.85
upper limit	4.1

Notes:

[71] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[72]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.19

Notes:

[72] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[73]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.075
upper limit	0.23

Notes:

[73] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[74]
P-value	= 0.49
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	1.79

Notes:

[74] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing

7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[75]
P-value	= 0.62
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.63

Notes:

[75] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[76]
P-value	= 0.39
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.97

Notes:

[76] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	L_15aTIV+½MF59 + N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[77]
P-value	= 0.15
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	2.42

Notes:

[77] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[78]
P-value	= 0.71
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.42

Notes:

[78] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2, and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with 0, ⅛, or ¼MF59 with 7.5µg aTIV/aQIV + ½MF59.
(B_15 TIV + 0MF59+ D_15 QIV + 0MF59:K_7.5 TIV+ ½MF59+ M_7.5 QIV+ ½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[79]
P-value	= 0.73
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.86

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.4

Notes:

[79] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[80]
P-value	= 0.59
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	1.56

Notes:

[80] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[81]
P-value	= 0.32
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.87

Notes:

[81] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[82]
P-value	= 0.8
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.33

Notes:

[82] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[83]
P-value	= 0.83
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.29

Notes:

[83] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing

7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[84]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.065
upper limit	0.24

Notes:

[84] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5TIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[85]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.077
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.042
upper limit	0.14

Notes:

[85] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(E_7.5TIV+⅛MF59 + F_7.5QIV+⅛MF59 : K_7.5TIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[86]
P-value	= 0.94
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	1.16

Notes:

[86] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[87]
P-value	= 0.79
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	1.46

Notes:

[87] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[88]
P-value	= 0.81
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.75

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	1.45

Notes:

[88] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	L_15aTIV+½MF59 + N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[89]
P-value	= 0.39
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	2.07

Notes:

[89] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[90]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.071
upper limit	0.2

Notes:

[90] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59. (B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5TIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[91]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.099
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.16

Notes:

[91] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59. (E_7.5TIV+⅛MF59 + F_7.5QIV+⅛MF59 : K_7.5TIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[92]
P-value	= 0.73
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.44

Notes:

[92] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2, and B/Florida 06 was assessed by comparing

7.5µg TIV/QIV and 15µg TIV/QIV each formulated with 0, ⅛, or ¼MF59 with 7.5µg TIV/QIV + ½MF59. (G_7.5 aTIV+ ¼MF59 + I_7.5 aQIV+ ¼MF59:K_7.5 aTIV+ ½MF59 + M_7.5 aQIV+ ½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[93]
P-value	= 0.77
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	1.39

Notes:

[93] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59. (H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[94]
P-value	= 0.76
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	1.42

Notes:

[94] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59. (L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+ ½MF59)

Comparison groups	L_15aTIV+½MF59 + N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[95]
P-value	= 0.62
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.56

Notes:

[95] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 1 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[96]
P-value	= 0.83
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.08

Notes:

[96] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 1 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[97]
P-value	= 0.87
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.91

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.07

Notes:

[97] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 1 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[98]
P-value	= 0.19
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.91
upper limit	1.27

Notes:

[98] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 1 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[99]
P-value	= 0.14
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	1.29

Notes:

[99] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 1 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[100]
P-value	= 0.92
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.05

Notes:

[100] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 1 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	L_15aTIV+½MF59 + N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[101]
P-value	= 0.75
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	1.11

Notes:

[101] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 29 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing

7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[102]
P-value	= 0.67
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.54

Notes:

[102] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 29 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[103]
P-value	= 0.9
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	1.2

Notes:

[103] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 29 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[104]
P-value	= 0.53
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.7

Notes:

[104] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 29 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[105]
P-value	= 0.17
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	2.3

Notes:

[105] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 29 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[106]
P-value	= 0.67
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.88

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.57

Notes:

[106] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 29 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	L_15aTIV+½MF59 + N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[107]
P-value	= 0.014
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.07
upper limit	3.25

Notes:

[107] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 50 (AC:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[108]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.1
upper limit	0.25

Notes:

[108] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 50 (BD:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59. (B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5TIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority[109]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.086
upper limit	0.21

Notes:

[109] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 50 (EF:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59. (E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5QIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[110]
P-value	= 0.9
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.18

Notes:

[110] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 50 (GI:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing

7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[111]
P-value	= 0.89
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.19

Notes:

[111] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 50 (HJ:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[112]
P-value	= 0.75
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.36

Notes:

[112] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL: Day 50 (LN:KM)

Statistical analysis description:

The superiority of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 was assessed by comparing 7.5µg TIV/aTIV/QIV/aQIV and 15µg TIV/aTIV/QIV/aQIV each formulated with nonadjuvanted/eighth/quarter adjuvanted MF59 with 7.5µg aTIV/aQIV+½MF59.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority[113]
P-value	= 0.18
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.96

Notes:

[113] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Primary: 4. To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group.

End point title	4. To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group.[114]

End point description:

Evaluating the superiority of GMTs against the second B strain (Malaysia) B_MY, the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV+½MF59 group.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

Notes:

[114] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	E_7.5aTIV+⅛MF59	F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	28	23	21
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.87 to 5.14)	5 (4.88 to 5.13)	5 (4.87 to 5.14)	5.17 (5.02 to 5.32)
B_MY (Day 29) (N= 17,22,19,18,18,19,21,40,32,38)	6.39 (5.18 to 7.87)	5 (4.16 to 6.01)	6.22 (4.16 to 7.58)	6.06 (4.95 to 7.43)
B_MY (Day 50)(N= 18,21,18,18,18,17,19,21,40,32,36)	11 (7.12 to 16)	9.68 (6.58 to 14)	9.68 (6.58 to 16)	42 (28 to 64)

End point values	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59	N_15aQIV+½MF59

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	22	24	22	25
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.86 to 5.14)	5.15 (5.01 to 5.29)	5 (4.86 to 5.14)	5 (4.87 to 5.13)
B_MY (Day 29) (N= 17,22,19,18,18,19,21,40,32,38)	5.83 (4.76 to 7.15)	6.55 (5.34 to 8.02)	6.22 (5.11 to 7.58)	7.19 (5.96 to 8.68)
B_MY (Day 50)(N= 18,21,18,18,18,17,19,21,40,32,36)	63 (42 to 96)	63 (41 to 96)	70 (47 to 106)	70 (48 to 103)

End point values	A_7.5TIV+0MF59 + B_15TIV+0MF59	G_7.5aTIV+¼ MF59 + H_15aTIV+¼MF59	K_7.5aTIV+½ MF59 + L_15aTIV+½MF59	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	46	42	47	
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.9 to 5.1)	5 (4.9 to 5.1)	5.07 (4.98 to 5.17)	
B_MY (Day 29) (N= 17,22,19,18,18,19,21,40,32,38)	5 (4.36 to 5.73)	5.45 (4.68 to 6.35)	5.79 (5.03 to 6.65)	
B_MY (Day 50)(N= 18,21,18,18,18,17,19,21,40,32,36)	5.74 (4.34 to 7.59)	11 (8.33 to 16)	14 (11 to 19)	

Statistical analyses

Statistical analysis title	B_MY: Day 1 (AB:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 1.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority[115]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.03

Notes:

[115] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (C:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 1.
(C_7.5QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority[116]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[116] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (D:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 1.
(D_15QIV+0MF59 : M_7.5QIV+½MF59)

Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[117]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[117] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (E:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 1.

(E_7.5aTIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	superiority[118]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[118] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (F:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV+½MF59 group for day 1.
(F_7.5 aQIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority[119]
P-value	= 0.53
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[119] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (GH:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV+½MF59 group for day 1.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59

Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority[120]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.04

Notes:

[120] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (I:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV+½MF59 group for day 1.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	I_7.5aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	superiority[121]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[121] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (J:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 1.
(J_15 aQIV + ¼MF59:M_7.5 aQIV+ ½MF59)

Comparison groups	J_15aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority[122]
P-value	= 0.071
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.07

Notes:

[122] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (KL:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV+½MF59 group for day1.
(K_7.5 aTIV+ ½MF59 + L_15 aTIV+ ½MF59:M_7.5 aQIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority[123]
P-value	= 0.2
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.05

Notes:

[123] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (N:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV+½MF59 group for day 1.
(N_15aQIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	N_15aQIV+½MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority[124]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[124] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (AB:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 29.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority[125]
P-value	= 0.96
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	1.02

Notes:

[125] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (C:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 29.
(C_7.5QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority[126]
P-value	= 0.43
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.37

Notes:

[126] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (D:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 29.

(D_15QIV+0MF59 : M_7.5QIV+½MF59)

Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[127]
P-value	= 0.94
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	1.05

Notes:

[127] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (E:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 29.
(E_7.5aTIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	E_7.5aTIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	superiority[128]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.32

Notes:

[128] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (F:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 29.
(F_7.5aQIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v M_7.5aQIV+½MF59

Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority[129]
P-value	= 0.57
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.29

Notes:

[129] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (GH:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 29.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority[130]
P-value	= 0.85
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.12

Notes:

[130] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (I:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 29.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	I_7.5aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	superiority[131]
P-value	= 0.67
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.94

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	1.24

Notes:

[131] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (J:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 29.
(J_15aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	J_15aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority[132]
P-value	= 0.36
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.4

Notes:

[132] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (KL:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 29.
(K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority[133]
P-value	= 0.72
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.18

Notes:

[133] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (N:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 29.
(N_15aQIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	N_15aQIV+½MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority[134]
P-value	= 0.15
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	1.52

Notes:

[134] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (AB:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 50.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority[135]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.082
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.05
upper limit	0.13

Notes:

[135] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (C:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 50.

(C_7.5QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority[136]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.086
upper limit	0.27

Notes:

[136] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (D:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 50.
(D_15QIV+0MF59 : M_7.5QIV+½MF59)

Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[137]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.079
upper limit	0.24

Notes:

[137] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (E:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 50.
(E_7.5aTIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59

Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	superiority[138]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.083
upper limit	0.26

Notes:

[138] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (F:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 50.
(F_7.5aQIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority[139]
P-value	= 0.96
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	1.08

Notes:

[139] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (GH:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 50.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority[140]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.16

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.097
upper limit	0.27

Notes:

[140] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (I:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 50.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	I_7.5aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	superiority[141]
P-value	= 0.64
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.61

Notes:

[141] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (J:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for Day 50.
(J_15aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	J_15aQIV+¼MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority[142]
P-value	= 0.65
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.6

Notes:

[142] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (KL:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 50.
(K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority[143]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.12
upper limit	0.33

Notes:

[143] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (N:M)

Statistical analysis description:

To evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the 7.5µg combined aTIV/aQIV + ½MF59 group for day 50.
(N_15aQIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	N_15aQIV+½MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority[144]
P-value	= 0.51
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	1.74

Notes:

[144] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Primary: 5. Evaluating the superiority of the antibody responses in terms of GMTs to the study vaccines (combining TIV/QIV/ aTIV/aQIV of identical antigen and adjuvant dose) to that of the marketed pediatric trivalent influenza vaccine Vaxigrip (7.5µg cTIV+0MF59).

End point title	5. Evaluating the superiority of the antibody responses in terms of GMTs to the study vaccines (combining TIV/QIV/ aTIV/aQIV of identical antigen and adjuvant dose) to that of the marketed pediatric trivalent influenza vaccine Vaxigrip (7.5µg cTIV+0MF59).[145]

End point description:

To evaluate the superiority of the antibody responses (GMTs) to the study vaccines (combining TIV/QIV/aTIV/aQIV of identical antigen and adjuvant dose) to that of the marketed pediatric trivalent influenza vaccine Vaxigrip (7.5µg cTIV+0MF59) for A/H1N1, A/H3N2 and first B-strain.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

Notes:

[145] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	Q_7.5cTIV+0MF59	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	26	49	49	44
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	9.74 (6.37 to 15)	6.4 (4.7 to 8.72)	6.54 (4.8 to 8.91)	8.15 (5.88 to 11)
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37)	42 (20 to 86)	14 (7.76 to 24)	12 (7.2 to 21)	109 (62 to 193)
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36)	261 (157 to 437)	57 (37 to 85)	69 (47 to 102)	533 (351 to 810)
A/H3N2 (Day 1)	5 (3.11 to 8.03)	7.38 (5.22 to 10)	7.22 (5.11 to 10)	7.96 (5.53 to 11)
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37)	22 (12 to 39)	19 (12 to 30)	12 (7.52 to 18)	91 (57 to 145)
A/H3N2 Day 50) (N=24,37,42,36,34,33,40,36)	133 (83 to 211)	73 (50 to 106)	60 (42 to 86)	518 (354 to 758)
B_FL (Day 1)	5.87 (5.03 to 6.84)	5.37 (4.8 to 6)	5.29 (4.73 to 5.92)	6.23 (5.54 to 7.02)
B_FL (Day 29) (N=23,37,43,37,35,33,41,37)	11 (6.46 to 18)	8.45 (5.64 to 13)	6.74 (4.63 to 9.8)	9.37 (6.26 to 14)
B_FL (Day 50) (N=24,37,42,36,34,33,40,36)	24 (16 to 36)	13 (9.45 to 18)	11 (7.98 to 15)	61 (43 to 84)

End point values	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59	H_15aTIV+¼MF59 + J_15aQIV+¼MF59	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59	L_15aTIV+½MF59 + N_15aQIV+½MF59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	44	44	49	45
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	8.41 (6.07 to 12)	7.83 (5.66 to 11)	7.7 (5.65 to 10)	7.58 (5.49 to 10)
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37)	118 (65 to 212)	149 (81 to 272)	118 (69 to 203)	220 (124 to 390)
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36)	481 (313 to 740)	576 (372 to 892)	529 (356 to 787)	718 (473 to 1092)

A/H3N2 (Day 1)	9.54 (6.62 to 14)	6.8 (4.72 to 9.79)	8.44 (5.97 to 12)	6.6 (4.6 to 9.46)
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37)	114 (71 to 184)	112 (68 to 183)	150 (96 to 232)	163 (103 to 259)
A/H3N2 Day 50) (N=24,37,42,36,34,33,40,36)	496 (335 to 734)	503 (338 to 748)	608 (423 to 872)	559 (382 to 819)
B_FL (Day 1)	6.33 (5.63 to 7.13)	5.16 (4.58 to 5.81)	5.8 (5.18 to 6.49)	5.48 (4.88 to 6.16)
B_FL (Day 29) (N=23,37,43,37,35,33,41,37)	13 (8.29 to 19)	8.45 (5.51 to 13)	9.59 (6.53 to 14)	18 (12 to 27)
B_FL (Day 50) (N=24,37,42,36,34,33,40,36)	61 (43 to 86)	69 (49 to 98)	81 (59 to 112)	101 (72 to 141)

Statistical analyses

Statistical analysis title	A/H1N1: Day 1 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[146]
P-value	= 0.94
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	1.11

Notes:

[146] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[147]
P-value	= 0.93
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.67

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	1.14

Notes:

[147] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[148]
P-value	= 0.74
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.43

Notes:

[148] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[149]
P-value	= 0.71
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.47

Notes:

[149] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[150]
P-value	= 0.79
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.37

Notes:

[150] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[151]
P-value	= 0.81
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.34

Notes:

[151] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 1 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[152]
P-value	= 0.82
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.46
upper limit	1.33

Notes:

[152] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5 cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[153]
P-value	= 0.99
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.13
upper limit	0.83

Notes:

[153] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[154]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.29

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.12
upper limit	0.72

Notes:

[154] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[155]
P-value	= 0.021
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.03
upper limit	6.56

Notes:

[155] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[156]
P-value	= 0.015
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.11
upper limit	7.15

Notes:

[156] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[157]
P-value	= 0.004
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	3.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.38
upper limit	9.14

Notes:

[157] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[158]
P-value	= 0.013
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.14
upper limit	6.98

Notes:

[158] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 29 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[159]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	5.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.09
upper limit	13

Notes:

[159] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[160]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.11
upper limit	0.42

Notes:

[160] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[161]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.26

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.14
upper limit	0.5

Notes:

[161] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[162]
P-value	= 0.017
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.05
upper limit	3.95

Notes:

[162] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[163]
P-value	= 0.037
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	3.59

Notes:

[163] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[164]
P-value	= 0.011
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.12
upper limit	4.32

Notes:

[164] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[165]
P-value	= 0.017
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.06
upper limit	3.87

Notes:

[165] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1: Day 50 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[166]
P-value	= 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.42
upper limit	5.33

Notes:

[166] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[167]
P-value	= 0.097
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	2.65

Notes:

[167] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[168]
P-value	= 0.11
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.44

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	2.6

Notes:

[168] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for Day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[169]
P-value	= 0.064
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	2.89

Notes:

[169] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(G_7.5 aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[170]
P-value	= 0.017
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.05
upper limit	3.47

Notes:

[170] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[171]
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	2.47

Notes:

[171] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[172]
P-value	= 0.04
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	3.03

Notes:

[172] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[173]
P-value	= 0.18
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	2.39

Notes:

[173] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5 cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[174]
P-value	= 0.65
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	1.82

Notes:

[174] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[175]
P-value	= 0.95
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.54

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.26
upper limit	1.11

Notes:

[175] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(E_7.5 aTIV+⅛MF59 + F_7.5 aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[176]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	4.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	2
upper limit	8.95

Notes:

[176] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[177]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.48
upper limit	11

Notes:

[177] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : Q_7.5 cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[178]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	5.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.41
upper limit	11

Notes:

[178] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[179]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	6.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.32
upper limit	14

Notes:

[179] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 29 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[180]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	7.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.57
upper limit	16

Notes:

[180] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[181]
P-value	= 0.97
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	1

Notes:

[181] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[182]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.46

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.25
upper limit	0.82

Notes:

[182] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[183]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	3.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.14
upper limit	7.13

Notes:

[183] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[184]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	3.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.03
upper limit	6.88

Notes:

[184] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[185]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	3.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.05
upper limit	7

Notes:

[185] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[186]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	4.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.54
upper limit	8.27

Notes:

[186] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 50 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[187]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	4.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.31
upper limit	7.71

Notes:

[187] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 1 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[188]
P-value	= 0.82
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.11

Notes:

[188] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 1 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[189]
P-value	= 0.86
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	1.09

Notes:

[189] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 1 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[190]
P-value	= 0.27
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	1.29

Notes:

[190] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 1 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[191]
P-value	= 0.22
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	1.31

Notes:

[191] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 1 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[192]
P-value	= 0.9
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.72
upper limit	1.07

Notes:

[192] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 1 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[193]
P-value	= 0.55
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.2

Notes:

[193] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 1 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[194]
P-value	= 0.75
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.13

Notes:

[194] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5 cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[195]
P-value	= 0.77
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	1.5

Notes:

[195] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(B_15 TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[196]
P-value	= 0.93
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.63

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.33
upper limit	1.18

Notes:

[196] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[197]
P-value	= 0.66
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	1.67

Notes:

[197] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[198]
P-value	= 0.32
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	2.25

Notes:

[198] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[199]
P-value	= 0.76
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	1.53

Notes:

[199] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[200]
P-value	= 0.64
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.69

Notes:

[200] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[201]
P-value	= 0.064
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	3.18

Notes:

[201] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 50 (AC:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[202]
P-value	= 0.99
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	0.92

Notes:

[202] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 50 (BD:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[203]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.45

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.27
upper limit	0.75

Notes:

[203] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 50 (EF:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[204]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.48
upper limit	4.24

Notes:

[204] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 50 (GI:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[205]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.48
upper limit	4.29

Notes:

[205] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 50 (HJ:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(H_15aTIV+¼MF59 + J_15QIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[206]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.68
upper limit	4.89

Notes:

[206] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 50 (KM:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2/B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority[207]
P-value	= 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	3.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.01
upper limit	5.65

Notes:

[207] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 50 (LN:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strainsA/H1N1, A/H3N2, B strain (Florida), the 7.5µg and 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority[208]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	4.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.47
upper limit	7.07

Notes:

[208] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Primary: 6. Superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined TIV/QIV+½MF59 group.

End point title	6. Superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined TIV/QIV+½MF59 group.[209]

End point description:

To assess immunogenicity in terms of GMT in order to evaluate the superiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined TIV/QIV+½MF59 group.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

Notes:

[209] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	28	26	23
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.87 to 5.13)	5 (4.88 to 5.12)	5 (4.88 to 5.13)	5 (4.87 to 5.13)
B_MY (Day 29) (N= 17,22,23,19,18,18,18,40,32)	6.39 (5.23 to 7.8)	5 (4.19 to 5.96)	5 (4.21 to 5.94)	6.22 (5.15 to 7.52)
B_MY (Day 50) (N= 18,21,24,18,18,18,17,40,32)	11 (7.24 to 16)	9.68 (6.68 to 14)	5.37 (3.8 to 7.59)	10 (6.97 to 15)

End point values	F_7.5aQIV+⅛MF59	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	24	22
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5.17 (5.03 to 5.31)	5 (4.87 to 5.14)	5.15 (5.02 to 5.28)	5 (4.87 to 5.14)
B_MY (Day 29) (N= 17,22,23,19,18,18,18,40,32)	6.06 (4.99 to 7.37)	5.83 (4.8 to 7.09)	6.55 (5.39 to 7.96)	6.22 (5.15 to 7.52)
B_MY (Day 50) (N= 18,21,24,18,18,18,17,40,32)	42 (28 to 63)	63 (43 to 95)	63 (42 to 94)	70 (48 to 101)

End point values	N_15aQIV+½MF59	A_7.5TIV+0MF59 + B_15TIV+0MF59	G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59	K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	25	46	42	47
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.88 to 5.13)	5 (4.91 to 5.09)	5 (4.9 to 5.1)	5.07 (4.98 to 5.17)
B_MY (Day 29) (N= 17,22,23,19,18,18,18,40,32)	7.19 (6 to 8.61)	5 (4.39 to 5.7)	5.45 (4.71 to 6.31)	5.79 (5.06 to 6.62)
B_MY (Day 50) (N= 18,21,24,18,18,18,17,40,32)	70 (48 to 101)	5.74 (4.39 to 7.51)	11 (8.44 to 15)	14 (11 to 19)

Statistical analyses

Statistical analysis title	B_MY: Day 1 (AB:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority[210]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.03

Notes:

[210] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (C:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(C_7.5 QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[211]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[211] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (D:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg /15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(D_15aQIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v D_15QIV+0MF59
Number of subjects included in analysis	54
Analysis specification	Pre-specified
Analysis type	superiority[212]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.03

Notes:

[212] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (E:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.

(E_7.5aTIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59
Number of subjects included in analysis	49
Analysis specification	Pre-specified
Analysis type	superiority[213]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[213] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (F:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.

(F_7.5QIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority[214]
P-value	= 0.04
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	1
upper limit	1.07

Notes:

[214] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-MY: Day 1 (GH:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.

(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59

Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority[215]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.03

Notes:

[215] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (I:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for Day 1.
(I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v I_7.5aQIV+¼MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority[216]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[216] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (J:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(J_15aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v J_15aQIV+¼MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[217]
P-value	= 0.056
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.07

Notes:

[217] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-MY: Day 1 (KL:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(K_7.5TIV+½MF59 + L_15TIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority[218]
P-value	= 0.17
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.05

Notes:

[218] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (M:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(M_7.5aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority[219]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[219] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (N:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(N_15 aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v N_15aQIV+½MF59
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority[220]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.04

Notes:

[220] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (AB:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority[221]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1.24

Notes:

[221] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (C:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(C_7.5QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v Q_7.5cTIV+0MF59

Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[222]
P-value	= 0.035
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.66

Notes:

[222] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY:Day 29 (D:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(D_15aQIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v D_15QIV+0MF59
Number of subjects included in analysis	54
Analysis specification	Pre-specified
Analysis type	superiority[223]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.28

Notes:

[223] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY:Day 29 (E:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(E_7.5aTIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v E_7.5aTIV+⅛MF59
Number of subjects included in analysis	49
Analysis specification	Pre-specified
Analysis type	superiority[224]
P-value	= 0.047
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.24

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.61

Notes:

[224] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (F:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(F_7.5QIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority[225]
P-value	= 0.073
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	1.57

Notes:

[225] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (GH:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority[226]
P-value	= 0.23
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.87
upper limit	1.37

Notes:

[226] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (I:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v I_7.5aQIV+¼MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority[227]
P-value	= 0.12
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.51

Notes:

[227] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (J:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(J_15aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v J_15aQIV+¼MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[228]
P-value	= 0.021
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.01
upper limit	1.7

Notes:

[228] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-MY: Day 29 (KL:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(K_7.5TIV+½MF59 + L_15TIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority[229]
P-value	= 0.095
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	1.44

Notes:

[229] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (M:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(M_7.5QIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority[230]
P-value	= 0.047
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.61

Notes:

[230] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29 (N:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29.
(N_15 aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v N_15aQIV+½MF59
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority[231]
P-value	= 0.002
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.44

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.12
upper limit	1.85

Notes:

[231] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY:Day 50 (AB:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority[232]
P-value	= 0.38
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.66

Notes:

[232] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (C:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(C_7.5 QIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[233]
P-value	= 0.005
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.18
upper limit	3.41

Notes:

[233] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (D:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(D_15aQIV+0MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v D_15QIV+0MF59
Number of subjects included in analysis	54
Analysis specification	Pre-specified
Analysis type	superiority[234]
P-value	= 0.012
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.09
upper limit	2.99

Notes:

[234] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (E:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(E_7.5aTIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	E_7.5aTIV+⅛MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	49
Analysis specification	Pre-specified
Analysis type	superiority[235]
P-value	= 0.007
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.14
upper limit	3.28

Notes:

[235] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (F:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(F_7.5QIV+⅛MF59 : Q_7.5cTIV+0MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v Q_7.5cTIV+0MF59

Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	superiority[236]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	7.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.65
upper limit	13

Notes:

[236] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-MY: Day 50 (GH:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority[237]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.34
upper limit	3.35

Notes:

[237] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (I:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(I_7.5aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v I_7.5aQIV+¼MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority[238]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	12

Confidence interval	
level	95 %
sides	2-sided
lower limit	6.97
upper limit	20

Notes:

[238] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (J:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(J_15aQIV+¼MF59 : Q_7.5cTIV+0MF59)

Comparison groups	J_15aQIV+¼MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority[239]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	12
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.81
upper limit	20

Notes:

[239] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-MY: Day 50 (KL:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(K_7.5TIV+½MF59 + L_15TIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority[240]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.68
upper limit	4.12

Notes:

[240] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (M:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(M_7.5QIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority[241]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	13
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.79
upper limit	22

Notes:

[241] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 50 (N:Q)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 50.
(N_15 aQIV+½MF59 : Q_7.5cTIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v N_15aQIV+½MF59
Number of subjects included in analysis	51
Analysis specification	Pre-specified
Analysis type	superiority[242]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	13
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.86
upper limit	22

Notes:

[242] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Primary: 7. Non-inferiority of the antibody responses (GMTs) to the study vaccines (combining TIV/QIV/aTIV/aQIV of identical antigen and adjuvant dose) to that of the marketed pediatric trivalent influenza vaccine Vaxigrip (7.5µg cTIV+0MF59).

End point title	7. Non-inferiority of the antibody responses (GMTs) to the study vaccines (combining TIV/QIV/aTIV/aQIV of identical antigen and adjuvant dose) to that of the marketed pediatric trivalent influenza vaccine Vaxigrip (7.5µg cTIV+0MF59).[243]

End point description:

To evaluate the non-inferiority of the antibody responses (GMTs) to the study vaccines (combining

TIV/QIV/aTIV/aQIV of identical antigen and adjuvant dose) to that of the marketed pediatric trivalent influenza vaccine Vaxigrip (7.5µg cTIV+0MF59) for A/H1N1, A/H3N2 and first B-strain.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

Notes:

[243] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	Q_7.5cTIV+0MF59	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	26	49	49	44
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	9.74 (6.39 to 15)	6.4 (4.71 to 8.71)	6.54 (4.81 to 8.89)	8.15 (5.89 to 11)
A/H1N1 (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	42 (21 to 85)	14 (7.83 to 24)	12 (7.26 to 21)	109 (62 to 191)
A/H3N2 (Day 1)	5 (3.14 to 7.97)	7.38 (5.25 to 10)	7.22 (5.14 to 10)	7.96 (5.56 to 11)
A/H3N2 (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	22 (12 to 38)	19 (12 to 29)	12 (7.68 to 17)	91 (59 to 142)
B_FL (Day 1)	5.87 (5.03 to 6.84)	5.37 (4.8 to 6)	5.29 (4.73 to 5.92)	6.23 (5.54 to 7.01)
B_FL (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	11 (6.49 to 18)	8.45 (5.67 to 13)	6.74 (4.65 to 9.76)	9.37 (6.28 to 14)

End point values	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59	H_15aTIV+¼MF59 + J_15aQIV+¼MF59	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59	L_15aTIV+½MF59 + N_15aQIV+½MF59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	44	44	49	45
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	8.41 (6.08 to 12)	7.83 (5.67 to 11)	7.7 (5.66 to 10)	7.58 (5.5 to 10)
A/H1N1 (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	118 (66 to 210)	149 (82 to 270)	529 (308 to 909)	220 (125 to 386)
A/H3N2 (Day 1)	9.54 (6.67 to 14)	6.8 (4.75 to 9.73)	8.44 (6.01 to 12)	6.6 (4.63 to 9.4)
A/H3N2 (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	114 (73 to 180)	112 (70 to 179)	608 (397 to 929)	163 (105 to 254)
B_FL (Day 1)	6.33 (5.63 to 7.13)	5.16 (4.59 to 5.81)	5.8 (5.19 to 6.49)	5.48 (4.88 to 6.16)
B_FL (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	13 (8.33 to 19)	8.45 (5.54 to 13)	81 (55 to 119)	18 (12 to 27)

End point values	O_15aTIV+full MF59 + P_15aQIV+full MF59			
Subject group type	Subject analysis set			
Number of subjects analysed	45			
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	7.4 (5.37 to 10)			
A/H1N1 (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	196 (111 to 346)			
A/H3N2 (Day 1)	6.7 (4.7 to 9.55)			
A/H3N2 (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	165 (105 to 258)			
B_FL (Day 1)	5.57 (4.96 to 6.26)			
B_FL (Day 29/50) (N= 23,37,43,37,35,33,40,37,36)	15 (9.71 to 22)			

Statistical analyses

Statistical analysis title	A/H1N1: Day 1 (AC:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[244]
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.28

Notes:

[244] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 1 (BD:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[245]
P-value	= 0.14
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.31

Notes:

[245] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 1 (EF:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1 .
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[246]
P-value	= 0.022
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.65

Notes:

[246] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 1 (GI:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[247]
P-value	= 0.016
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.71

Notes:

[247] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 1 (HJ:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[248]
P-value	= 0.033
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.59

Notes:

[248] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 1 (LN:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(L_15aTIV+½MF59 + N_15 aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[249]
P-value	= 0.044
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.98

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	1.53

Notes:

[249] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 1 (OP:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : K_7.5aTIV+½MF59+M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[250]
P-value	= 0.055
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.62
upper limit	1.5

Notes:

[250] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 1 (Q:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(Q_7.5cTIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[251]
P-value	= 0.009
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	2.13

Notes:

[251] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (AC:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[252]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.026
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.012
upper limit	0.057

Notes:

[252] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (BD:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[253]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.023
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.011
upper limit	0.049

Notes:

[253] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (EF:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the

7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(E_7.5 aTIV+⅛MF59 + F_7.5 aQIV+⅛ MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[254]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.094
upper limit	0.45

Notes:

[254] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (GI:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[255]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.1
upper limit	0.49

Notes:

[255] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (HJ:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50 .
(H_15 aTIV+¼MF59 + J_15 aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[256]
P-value	= 0.98
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.13
upper limit	0.63

Notes:

[256] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (LN:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2/B strain (Florida), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for Day 29/Day 50 .
(L_15aTIV+½MF59 + N_15 aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[257]
P-value	= 0.88
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	0.91

Notes:

[257] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (OP:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(O_15aTIV+fullMF59 + P_15 aQIV+fullMF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[258]
P-value	= 0.93
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.37

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.17
upper limit	0.81

Notes:

[258] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (Q:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(Q_7.5 cTIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[259]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.079
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.032
upper limit	0.19

Notes:

[259] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (AC:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[260]
P-value	= 0.14
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.41

Notes:

[260] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (BD:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(B_15 TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[261]
P-value	= 0.16
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.38

Notes:

[261] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (EF:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(E_7.5 aTIV+⅛MF59 + F_7.5 aQIV+⅛ MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[262]
P-value	= 0.087
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	1.54

Notes:

[262] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (GI:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the

7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[263]
P-value	= 0.019
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.85

Notes:

[263] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (HJ:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[264]
P-value	= 0.23
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.32

Notes:

[264] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (LN:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(L_15aTIV+½MF59 + N_15 aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	H_15aTIV+¼MF59 + J_15aQIV+¼MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	non-inferiority[265]
P-value	= 0.27
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	1.28

Notes:

[265] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (OP:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(O_15aTIV+fullMF59 + P_15 aQIV+fullMF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[266]
P-value	= 0.25
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.3

Notes:

[266] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (Q:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(Q_7.5cTIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[267]
P-value	= 0.66
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.59

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.33
upper limit	1.05

Notes:

[267] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (AC:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[268]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.031
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.017
upper limit	0.056

Notes:

[268] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (BD:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the non adjuvanted 7.5µg cTIV for Day 29/Day 50 .
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[269]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.019
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.011
upper limit	0.034

Notes:

[269] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (EF:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛ MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[270]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.081
upper limit	0.28

Notes:

[270] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (GI:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[271]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.1
upper limit	0.35

Notes:

[271] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (HJ:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the

7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(H_15 aTIV + ¼MF59 + J_15 aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[272]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.098
upper limit	0.35

Notes:

[272] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (LN:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[273]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.15
upper limit	0.5

Notes:

[273] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (OP:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59

Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[274]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.15
upper limit	0.5

Notes:

[274] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (Q:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(Q_7.5cTIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[275]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.035
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.018
upper limit	0.072

Notes:

[275] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (AC:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[276]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.93

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.08

Notes:

[276] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (BD:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(B_15 TIV+ 0MF59 + D_15QIV+0MF59:K_7.5aTIV+½MF59+M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[277]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.07

Notes:

[277] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (EF:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛ MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[278]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.91
upper limit	1.26

Notes:

[278] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (GI:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[279]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	1.28

Notes:

[279] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (HJ:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(H_15 aTIV + ¼MF59+J_15 aQIV +¼MF59:K_7.5aTIV+½MF59+M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[280]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.05

Notes:

[280] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (LN:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the

7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[281]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	1.11

Notes:

[281] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (OP:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[282]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.13

Notes:

[282] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (Q:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 1.
(Q_7.5cTIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59

Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[283]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.22

Notes:

[283] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (AC:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(A_7.5TIV+0MF59 + C_7.5QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[284]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.18

Notes:

[284] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (BD:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v B_15TIV+0MF59 + D_15QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[285]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.083

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.049
upper limit	0.14

Notes:

[285] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (EF:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛ MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[286]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.066
upper limit	0.2

Notes:

[286] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (GI:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[287]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.088
upper limit	0.27

Notes:

[287] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL: Day 29/Day 50 (HJ:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[288]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.059
upper limit	0.18

Notes:

[288] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL: Day 29/Day 50 (LN:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[289]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.13
upper limit	0.38

Notes:

[289] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL: Day 29/Day 50 (OP:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the

7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[290]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.1
upper limit	0.31

Notes:

[290] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (Q:KM)

Statistical analysis description:

To evaluate the non-inferiority of GMTs against the three strains A/H1N1, A/H3N2, B strain (Florida), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content was pooled and compared with the non adjuvanted 7.5µg cTIV for day 29/day 50.
(Q_7.5cTIV+0MF59 : K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59)

Comparison groups	Q_7.5cTIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[291]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.07
upper limit	0.25

Notes:

[291] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Primary: 8. Non-inferiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined TIV/QIV + ½MF59 group.

End point title	8. Non-inferiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined TIV/QIV + ½MF59 group.[292]

End point description:

To evaluate the non-inferiority of GMTs against the second B strain (Malaysia), the 7.5µg and 15µg TIV groups of identical MF59 content were pooled and compared with the 7.5µg combined TIV/QIV + ½MF59 group.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

Notes:

[292] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	28	26	23
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.86 to 5.14)	5 (4.87 to 5.13)	5 (4.87 to 5.14)	5 (4.86 to 5.14)
B_MY (Day 29/50)	6.39 (4.81 to 8.47)	5 (3.9 to 6.41)	5 (3.92 to 6.38)	6.22 (4.76 to 8.13)

End point values	F_7.5aQIV+⅛MF59	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	24	22
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5.17 (5.02 to 5.32)	5 (4.86 to 5.15)	5.15 (5 to 5.29)	5 (4.86 to 5.15)
B_MY (Day 29/50)	6.06 (4.61 to 7.98)	5.83 (4.43 to 7.68)	6.55 (4.97 to 8.62)	70 (54 to 92)

End point values	N_15aQIV+½MF59	O_15aTIV+fullMF59	P_15aQIV+fullMF59	A_7.5TIV+0MF59 + B_15TIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	25	24	21	46
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.87 to 5.14)	5 (4.86 to 5.14)	5.17 (5.02 to 5.32)	5 (4.9 to 5.1)
B_MY (Day 29/50)	7.19 (5.57 to 9.27)	5.4 (4.1 to 7.11)	11 (8.36 to 14)	5 (4.16 to 6.01)

End point values	G_7.5aTIV+¼MF59 +	K_7.5aTIV+½MF59 +		

	H_15aTIV+¼MF59	L_15aTIV+½MF59		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	42	47		
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.9 to 5.11)	5.07 (4.97 to 5.18)		
B_MY (Day 29/50)	5.45 (4.44 to 6.7)	5.79 (4.79 to 6.99)		

Statistical analyses

Statistical analysis title	B_MY: Day 1 (AB:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	non-inferiority[293]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.04

Notes:

[293] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (C:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(C_7.5QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[294]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[294] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (D:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(D_15QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	non-inferiority[295]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[295] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (E:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(E_7.5aTIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[296]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[296] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (F:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(F_7.5aQIV+⅛ MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v F_7.5aQIV+⅛MF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	non-inferiority[297]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[297] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (GH:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	non-inferiority[298]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[298] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (I:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v I_7.5aQIV+¼MF59

Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	non-inferiority[299]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[299] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (J:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(J_15aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v J_15aQIV+¼MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[300]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.07

Notes:

[300] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (KL:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	non-inferiority[301]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.05

Notes:

[301] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (N:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(N_15aQIV+½MF59 : M_7.5aQIV+½MF59)

Comparison groups	N_15aQIV+½MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	non-inferiority[302]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[302] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (O:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(O_15aTIV+fullMF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v O_15aTIV+fullMF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[303]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[303] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (P:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(P_15aQIV+fullMF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v P_15aQIV+fullMF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	non-inferiority[304]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[304] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (Q:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 1.
(Q_7.5cTIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	non-inferiority[305]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[305] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day50 (AB:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day50.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59

Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	non-inferiority[306]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.071
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.051
upper limit	0.098

Notes:

[306] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (C:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(C_7.5QIV+0MF59 : M_7.5 aQIV+½MF59)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[307]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.091
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.061
upper limit	0.13

Notes:

[307] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (D:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(D_15QIV+0MF59 : M_7.5aQIV+½MF59)

Comparison groups	D_15QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	non-inferiority[308]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.071

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.049
upper limit	0.1

Notes:

[308] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (E:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(E_7.5aTIV+⅛MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v E_7.5aTIV+⅛MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[309]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.088
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.061
upper limit	0.13

Notes:

[309] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (F:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(F_7.5aQIV+⅛ MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v F_7.5aQIV+⅛MF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	non-inferiority[310]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.086
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.059
upper limit	0.13

Notes:

[310] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (GH:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	non-inferiority[311]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.077
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.055
upper limit	0.11

Notes:

[311] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (I:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(I_7.5aQIV+¼MF59 : M_7.5aQIV+½MF59)

Comparison groups	M_7.5aQIV+½MF59 v I_7.5aQIV+¼MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	non-inferiority[312]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.083
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.056
upper limit	0.12

Notes:

[312] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (J:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(J_15 aQIV +¼MF59:M_7.5 aQIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v J_15aQIV+¼MF59

Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[313]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.093
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.063
upper limit	0.14

Notes:

[313] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (KL:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(K_7.5 aTIV+½MF59 + L_15 aTIV+ ½MF59:M_7.5 aQIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	non-inferiority[314]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.082
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.059
upper limit	0.11

Notes:

[314] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (N:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(N_15 aQIV +½MF59:M_7.5 aQIV+ ½MF59)

Comparison groups	N_15aQIV+½MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	non-inferiority[315]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.071
upper limit	0.15

Notes:

[315] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (O:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(N_15 aQIV +½MF59:M_7.5 aQIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v O_15aTIV+fullMF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[316]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.077
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.052
upper limit	0.11

Notes:

[316] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (P:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(P_15 aQIV+ fullMF59:M_7.5 aQIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v P_15aQIV+fullMF59
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	non-inferiority[317]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.11
upper limit	0.23

Notes:

[317] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (Q:M)

Statistical analysis description:

To evaluate the Non-inferiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content were pooled and compared with the half adjuvanted 7.5µg aQIV for Day 29/Day 50.
(Q_7.5cTIV+ 0MF59:M_7.5 aQIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v Q_7.5cTIV+0MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	non-inferiority[318]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.071
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.049
upper limit	0.1

Notes:

[318] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Primary: 9. Assessing Geometric Mean Titer (GMTs) to Compare the nonadjuvanted pediatric vaccine (7.5 TIV/QIV+0MF59) non adjuvanted vaccine.

End point title	9. Assessing Geometric Mean Titer (GMTs) to Compare the nonadjuvanted pediatric vaccine (7.5 TIV/QIV+0MF59) non adjuvanted vaccine.[319]

End point description:

To evaluate immunogenicity in terms of GMT if any of the vaccine groups could induce antibody titers after one vaccination that were non-inferior to the antibody titers after two 7.5µg TIV/QIV+0MF59 vaccinations, the GMTs at day 29 of the vaccine group combinations were compared with those at day 50 in the 7.5µg TIV/QIV+ 0MF59 group for three strains.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1 and Day 29/50

Notes:

[319] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	Q_7.5cTIV+0MF59	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	26	49	49	44
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	9.74 (6.39 to 15)	6.4 (4.71 to 8.71)	6.54 (4.81 to 8.89)	8.15 (5.89 to 11)
A/H1N1 (Day29/Day50)(N=23,37,43,37,35,33,4	42 (21 to 85)	14 (7.38 to 24)	12 (7.2 to 21)	109 (62 to 193)

A/H3N2 (Day 1)	5 (3.14 to 7.97)	7.38 (5.25 to 10)	7.22 (5.14 to 10)	7.96 (5.56 to 11)
A/H3N2 (Day29/Day50)(N=23,37,43,37,35,33,4	22 (12 to 39)	19 (12 to 29)	12 (7.56 to 18)	91 (58 to 144)
B_FL (Day 1)	5.87 (5.03 to 6.84)	5.37 (4.8 to 6)	6.74 (4.6 to 9.87)	6.23 (5.54 to 7.01)
B_FL (Day29/Day50) (N=23,37,43,37,35,33,41,37,36)	11 (6.49 to 18)	8.45 (5.67 to 13)	5.29 (4.73 to 5.92)	9.37 (6.2 to 14)

End point values	G_7.5aTIV+¼ MF59 + I_7.5aQIV+¼M F59	H_15aTIV+¼M F59 + J_15aQIV+¼M F59	K_7.5aTIV+½ MF59 + M_7.5aQIV+½ MF59	L_15aTIV+½M F59 + N_15aQIV+½M F59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	44	44	49	44
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	8.41 (6.08 to 12)	7.83 (5.67 to 11)	7.7 (5.66 to 10)	7.58 (5.5 to 10)
A/H1N1 (Day29/Day50)(N=23,37,43,37,35,33,4	118 (65 to 212)	149 (81 to 272)	118 (69 to 203)	220 (124 to 389)
A/H3N2 (Day 1)	9.54 (6.67 to 14)	6.8 (4.75 to 9.73)	8.44 (6.01 to 12)	6.6 (4.63 to 9.4)
A/H3N2 (Day29/Day50)(N=23,37,43,37,35,33,4	114 (71 to 183)	112 (69 to 182)	150 (97 to 231)	163 (103 to 258)
B_FL (Day 1)	6.33 (5.63 to 7.13)	5.16 (4.59 to 5.81)	5.8 (5.19 to 6.49)	5.48 (4.88 to 6.16)
B_FL (Day29/Day50) (N=23,37,43,37,35,33,41,37,36)	13 (8.22 to 19)	8.45 (5.47 to 13)	9.59 (6.48 to 14)	18 (12 to 27)

End point values	O_15aTIV+full MF59 + P_15aQIV+full MF59			
Subject group type	Subject analysis set			
Number of subjects analysed	45			
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	7.4 (5.37 to 10)			
A/H1N1 (Day29/Day50)(N=23,37,43,37,35,33,4	196 (110 to 349)			
A/H3N2 (Day 1)	6.7 (4.7 to 9.55)			
A/H3N2 (Day29/Day50)(N=23,37,43,37,35,33,4	165 (104 to 262)			
B_FL (Day 1)	5.57 (4.96 to 6.26)			
B_FL (Day29/Day50) (N=23,37,43,37,35,33,41,37,36)	15 (9.59 to 22)			

Statistical analyses

Statistical analysis title	A/H1N1:Day 1 (BD:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+ QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[320]
P-value	= 0.028
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.58

Notes:

[320] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1:Day 1 (EF:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[321]
P-value	= 0.002
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1.99

Notes:

[321] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 1 (GI:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[322]
P-value	= 0.002
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	2.05

Notes:

[322] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 1 (HJ:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[323]
P-value	= 0.004
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.91

Notes:

[323] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 1 (KM:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of

nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[324]
P-value	= 0.004
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.86

Notes:

[324] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1:Day 1 (LN:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(L_15aTIV+½MF59 + N_15 aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[325]
P-value	= 0.006
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.84

Notes:

[325] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H1N1:Day 1 (OP:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	O_15aTIV+fullMF59 + P_15aQIV+fullMF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59

Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[326]
P-value	= 0.008
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.8

Notes:

[326] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 1 (Q:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted cTIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(Q_7.5cTIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[327]
P-value	= 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	2.56

Notes:

[327] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 29/Day 50 (BD:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted TIV+QIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[328]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.22

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.099
upper limit	0.47

Notes:

[328] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 29/Day 50 (EF:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted TIV+QIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[329]
P-value	= 0.005
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	4.32

Notes:

[329] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1: Day 29/Day 50 (GI:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : A_7.5TIV+0MF59+C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[330]
P-value	= 0.003
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	4.72

Notes:

[330] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 29/Day 50 (HJ:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : A_7.5TIV+0MF59+C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[331]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.14
upper limit	6.03

Notes:

[331] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 29/Day 50 (KM:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[332]
P-value	= 0.002
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.95
upper limit	4.59

Notes:

[332] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 29/Day 50 (LN:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of

nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[333]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	3.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.74
upper limit	8.72

Notes:

[333] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 29/Day 50 (OP:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+ QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on Day 29/Day 50.
(O_15 aTIV+fullMF59 + P_15 aQIV+fullMF59:A_7.5 TIV+0MF59 + C_7.5 QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[334]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	3.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.54
upper limit	7.8

Notes:

[334] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H1N1:Day 29/Day 50 (Q:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted cTIV to that of 2 doses of nonadjuvanted 7.5µg/antigen TIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(Q_7.5cTIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59

Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[335]
P-value	= 0.42
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	1.86

Notes:

[335] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2 : Day 1 (BD:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted TIV+QIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[336]
P-value	= 0.061
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	1.58

Notes:

[336] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2: Day 1 (EF:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(E_7.5aTIV+⅛MF59 + F_7.5 aQIV+⅛MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[337]
P-value	= 0.029
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.08

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.77

Notes:

[337] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (GI:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[338]
P-value	= 0.005
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	2.12

Notes:

[338] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2:Day 1 (HJ:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[339]
P-value	= 0.1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.51

Notes:

[339] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2:Day 1 (KM:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[340]
P-value	= 0.015
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	1.85

Notes:

[340] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (LN:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[341]
P-value	= 0.12
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.46

Notes:

[341] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2: Day 1 (OP:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of

nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[342]
P-value	= 0.11
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.48

Notes:

[342] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2:Day 1 (Q:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted cTIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(Q_7.5cTIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[343]
P-value	= 0.48
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.38
upper limit	1.21

Notes:

[343] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2: Day 29/Day 50 (BD:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 15µg/antigen adjuvanted TIV+QIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(B_15TIV+0MF59 + D_15QIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[344]
P-value	= 1
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.085
upper limit	0.3

Notes:

[344] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2:Day 29/Day 50 (EF:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/50.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[345]
P-value	= 0.029
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	2.39

Notes:

[345] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	A/H3N2:Day 29/Day 50 (GI:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[346]
P-value	= 0.006
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.57

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	3.03

Notes:

[346] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2:Day 29/Day 50 (HJ:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[347]
P-value	< 0.007
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	2.99

Notes:

[347] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2:Day 29/Day 50 (KM:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[348]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.09
upper limit	3.86

Notes:

[348] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2:Day 29/Day 50 (LN:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[349]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.17
upper limit	4.28

Notes:

[349] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2:Day 29/Day 50 (OP:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[350]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.18
upper limit	4.34

Notes:

[350] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	A/H3N2:Day 29/Day 50 (Q:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of

nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(Q_7.5cTIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[351]
P-value	= 0.98
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.14
upper limit	0.62

Notes:

[351] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL:Day 1 (BD:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(B_15TIV+0MF59 + D_15QIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[352]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.15

Notes:

[352] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL:Day 1 (EF:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[353]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.37

Notes:

[353] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL:Day 1 (GI:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[354]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	1
upper limit	1.39

Notes:

[354] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL:Day 1 (HJ:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[355]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.96

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.13

Notes:

[355] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (KM:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[356]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.27

Notes:

[356] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (LN:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[357]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.87
upper limit	1.2

Notes:

[357] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL:Day 1 (OP:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+ QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on Day 1.
(O_15 aTIV+fullMF59 + P_15 aQIV+fullMF59:A_7.5 TIV+0MF59 + C_7.5 QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[358]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	1.22

Notes:

[358] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 1 (Q:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 1.
(Q_7.5cTIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[359]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.32

Notes:

[359] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (BD:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on

day 29/day 50.
(B_15TIV+0MF59 + D_15QIV+MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	B_15TIV+0MF59 + D_15QIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[360]
P-value	= 0.82
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	0.9

Notes:

[360] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL:Day 29/Day 50 (EF:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+ QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on Day 29/Day 50.
(E_7.5 aTIV+⅛MF59 + F_7.5 aQIV+⅛MF59:A_7.5 TIV + 0MF59 + C_7.5 QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[361]
P-value	= 0.42
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	1.28

Notes:

[361] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL:Day 29/Day 50 (GI:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[362]
P-value	= 0.12
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.73

Notes:

[362] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL:Day 29/Day 50 (HJ:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(H_15aTIV+¼MF59 + J_15aQIV+¼MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v H_15aTIV+¼MF59 + J_15aQIV+¼MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[363]
P-value	= 0.55
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.35
upper limit	1.17

Notes:

[363] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_FL:Day 29/Day 50 (KM:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	non-inferiority[364]
P-value	= 0.38
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.73

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	1.29

Notes:

[364] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (LN:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(L_15aTIV+½MF59 + N_15aQIV+½MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v L_15aTIV+½MF59 + N_15aQIV+½MF59
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	non-inferiority[365]
P-value	= 0.009
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	2.44

Notes:

[365] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL:Day 29/Day 50 (OP:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(O_15aTIV+fullMF59 + P_15aQIV+fullMF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	A_7.5TIV+0MF59 + C_7.5QIV+0MF59 v O_15aTIV+fullMF59 + P_15aQIV+fullMF59
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	non-inferiority[366]
P-value	= 0.046
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.62
upper limit	1.99

Notes:

[366] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_FL: Day 29/Day 50 (Q:AC)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen adjuvanted aTIV+aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigenTIV+QIV, for the three strains A/H1N1,A/H3N2 and B/Florida (B_FL) on day 29/day 50.
(Q_7.5cTIV+0MF59 : A_7.5TIV+0MF59 + C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v A_7.5TIV+0MF59 + C_7.5QIV+0MF59
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	non-inferiority[367]
P-value	= 0.27
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.42
upper limit	1.6

Notes:

[367] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Primary: 10. Assessing Geometric Mean Titers (GMTs) to evaluate non-inferior antibody responses to the second influenza B strain when compared with two 7.5µg QIV+0MF59 vaccinations.

End point title	10. Assessing Geometric Mean Titers (GMTs) to evaluate non-inferior antibody responses to the second influenza B strain when compared with two 7.5µg QIV+0MF59 vaccinations.[368]

End point description:

To assess immunogenicity in terms of GMT in order to evaluate non-inferior antibody responses to the second influenza B strain when compared with two 7.5µg QIV+0MF59 vaccinations, GMTs at day 29 from the other groups were compared with those at day 50 from 7.5µg QIV+0MF59 strains.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1 and Day 29/50

Notes:

[368] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	28	26	23
Units: Titers				
geometric mean (confidence interval 95%)				
D1	5 (4.86 to 5.14)	5 (4.87 to 5.13)	5 (4.87 to 5.14)	5 (4.86 to 5.14)

D29/50(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38	11 (8.26 to 14)	5 (3.92 to 6.37)	5 (3.95 to 6.34)	6.22 (4.8 to 8.08)

End point values	F_7.5aQIV+⅛MF59	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	24	22
Units: Titers				
geometric mean (confidence interval 95%)				
D1	5.17 (5.02 to 5.32)	5 (4.86 to 5.15)	5.15 (5 to 5.29)	5 (4.86 to 5.15)
D29/50(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38	6.06 (4.64 to 7.92)	5.83 (4.46 to 7.62)	6.55 (5.01 to 8.56)	6.22 (4.8 to 8.08)

End point values	N_15aQIV+½MF59	O_15aTIV+full MF59	P_15aQIV+full MF59	A_7.5TIV+0MF59 + B_15TIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	25	24	21	46
Units: Titers				
geometric mean (confidence interval 95%)				
D1	5 (4.87 to 5.14)	5 (4.86 to 5.14)	5.17 (5.02 to 5.32)	5 (4.9 to 5.11)
D29/50(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38	7.19 (5.61 to 9.21)	5.4 (4.13 to 7.06)	11 (8.42 to 14)	5.74 (4.32 to 7.64)

End point values	G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59	K_7.5aTIV+½MF59 + L_15aTIV+½MF59		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	42	47		
Units: Titers				
geometric mean (confidence interval 95%)				
D1	5 (4.9 to 5.11)	5.07 (4.97 to 5.18)		
D29/50(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38	5.45 (4.46 to 6.67)	5.79 (4.81 to 6.96)		

Statistical analyses

Statistical analysis title	B_MY: Day 1 (AB:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on Day 1.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	non-inferiority[369]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.04

Notes:

[369] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (D:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(D_15QIV+0MF59 : C_7.5QIV+0MF59)

Comparison groups	D_15QIV+0MF59 v C_7.5QIV+0MF59
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	non-inferiority[370]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[370] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (E:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on Day 1.
(E_7.5 aTIV+ ⅛MF59:C_7.5 QIV + 0MF59)

Comparison groups	C_7.5QIV+0MF59 v E_7.5aTIV+⅛MF59

Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	non-inferiority[371]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[371] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (F:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(F_7.5aQIV+⅛MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v F_7.5aQIV+⅛MF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[372]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[372] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (GH:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	non-inferiority[373]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.04

Notes:

[373] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (I:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(I_7.5aQIV+¼MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v I_7.5aQIV+¼MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[374]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[374] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (J:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(J_15aQIV+¼MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v J_15aQIV+¼MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	non-inferiority[375]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.07

Notes:

[375] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (KL:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	non-inferiority[376]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.05

Notes:

[376] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (M:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(M_7.5aQIV+½MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	non-inferiority[377]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[377] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 1 (N:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(N_15aQIV+½MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v N_15aQIV+½MF59

Number of subjects included in analysis	49
Analysis specification	Pre-specified
Analysis type	non-inferiority[378]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[378] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (O:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(O_15aTIV+fullMF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v O_15aTIV+fullMF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	non-inferiority[379]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[379] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (P:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(P_15aQIV+fullMF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v P_15aQIV+fullMF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[380]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[380] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 1 (Q:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 1.
(Q_7.5cTIV+0MF59 : C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v C_7.5QIV+0MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	non-inferiority[381]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[381] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (AB:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50.
(A_7.5TIV+0MF59 + B_15TIV+0MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	non-inferiority[382]
P-value	= 0.99
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	0.64

Notes:

[382] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (D:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50.
(D_15QIV+0MF59 : C_7.5QIV+0MF59)

Comparison groups	D_15QIV+0MF59 v C_7.5QIV+0MF59
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	non-inferiority[383]
P-value	= 0.98
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	0.66

Notes:

[383] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (E:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50.
(E_7.5aTIV+⅛MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v E_7.5aTIV+⅛MF59
Number of subjects included in analysis	47
Analysis specification	Pre-specified
Analysis type	non-inferiority[384]
P-value	= 0.79
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	0.84

Notes:

[384] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (F:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on Day 29/Day 50.
(F_7.5 aQIV+⅛MF59:C_7.5 QIV + 0MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v C_7.5QIV+0MF59

Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[385]
P-value	= 0.82
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.38
upper limit	0.82

Notes:

[385] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (GH:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50. (G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	non-inferiority[386]
P-value	= 0.95
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.36
upper limit	0.71

Notes:

[386] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (I:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50. (I_7.5aQIV+¼MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v I_7.5aQIV+¼MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[387]
P-value	= 0.87
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.54

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	0.79

Notes:

[387] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (J:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50.
(J_15 aQIV + ¼MF59:C_7.5 QIV + 0MF59)

Comparison groups	C_7.5QIV+0MF59 v J_15aQIV+¼MF59
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	non-inferiority[388]
P-value	= 0.7
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.42
upper limit	0.89

Notes:

[388] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (KL:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50.
(K_7.5aTIV+½MF59 + L_15aTIV+½MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	non-inferiority[389]
P-value	= 0.91
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	0.74

Notes:

[389] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (M:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50. (M_7.5aQIV+½MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v M_7.5aQIV+½MF59
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	non-inferiority[390]
P-value	= 0.79
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	0.84

Notes:

[390] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (N:C)

Statistical analysis description:

NoNon-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50. (N_15aQIV+½MF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v N_15aQIV+½MF59
Number of subjects included in analysis	49
Analysis specification	Pre-specified
Analysis type	non-inferiority[391]
P-value	= 0.51
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.46
upper limit	0.96

Notes:

[391] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0.67.

Statistical analysis title	B_MY: Day 29/Day 50 (O:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50. (O_15aTIV+fullMF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v O_15aTIV+fullMF59

Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	non-inferiority[392]
P-value	= 0.94
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	0.73

Notes:

[392] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (P:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50. (P_15aQIV+fullMF59 : C_7.5QIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v P_15aQIV+fullMF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	non-inferiority[393]
P-value	= 0.015
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.49

Notes:

[393] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Statistical analysis title	B_MY: Day 29/Day 50 (Q:C)

Statistical analysis description:

Non-inferiority of study vaccine of 7.5µg/antigen and 15µg/antigen adjuvanted aQIV to that of 2 doses of nonadjuvanted 7.5µg/antigen QIV, for strains B_Malaysia (B_MY) on day 29/day 50. (Q_7.5cTIV+0MF59 : C_7.5QIV+0MF59)

Comparison groups	Q_7.5cTIV+0MF59 v C_7.5QIV+0MF59
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	non-inferiority[394]
P-value	= 0.98
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.46

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	0.66

Notes:

[394] - Non-inferiority was to be shown if the lower margin of the 95% confidence interval (CI) was >0. 67.

Primary: 11. Assessing Geometric Mean Titer (GMTs) to evaluate whether the addition of a second influenza B strain (Malaysia) to a TIV (QIV) increases the antibody responses to this influenza B strain.

End point title	11. Assessing Geometric Mean Titer (GMTs) to evaluate whether the addition of a second influenza B strain (Malaysia) to a TIV (QIV) increases the antibody responses to this influenza B strain.[395]

End point description:

To assess immunogenicity in terms of GMT in order to evaluate if the second influenza B strain (Malaysia) is immunogenic in QIV, antibody responses to B/Malaysia induced by QIV were assessed for superiority to those of TIV at day 29 (for groups that only received one vaccination [i.e., formulated with full MF59]) or at day 50 (for groups that received two vaccinations).
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29/Day 50

Notes:

[395] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	E_7.5aTIV+⅛MF59	F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	28	23	21
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.86 to 5.15)	5 (4.87 to 5.14)	5 (4.85 to 5.15)	5.17 (5.01 to 5.33)
B_MY (Day 29/50) (N=18,21,18,18,18,17,19,21,22,18)	11 (7.06 to 17)	9.68 (6.53 to 14)	10 (6.8 to 16)	42 (28 to 65)

End point values	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59	N_15aQIV+½MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	22	24	22	25
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.85 to 5.15)	5.15 (5 to 5.3)	5 (4.85 to 5.15)	5 (4.86 to 5.14)
B_MY (Day 29/50) (N=18,21,18,18,18,17,19,21,22,18)	63 (42 to 97)	63 (40 to 97)	70 (47 to 106)	70 (47 to 104)

End point values	O_15aTIV+full MF59	P_15aQIV+full MF59	A_7.5TIV+0MF59 + B_15TIV+0MF59	G_7.5aTIV+¼ MF59 + H_15aTIV+¼MF59
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	24	21	46	42
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.86 to 5.15)	5.17 (5.01 to 5.33)	5 (4.9 to 5.11)	5 (4.89 to 5.11)
B_MY (Day 29/50) (N=18,21,18,18,18,17,19,21,22,18)	5.33 (3.63 to 7.82)	11 (7.2 to 17)	5.74 (4.32 to 7.64)	11 (8.28 to 16)

End point values	K_7.5aTIV+½ MF59 + L_15aTIV+½MF59			
Subject group type	Subject analysis set			
Number of subjects analysed	47			
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5.07 (4.97 to 5.18)			
B_MY (Day 29/50) (N=18,21,18,18,18,17,19,21,22,18)	14 (10 to 19)			

Statistical analyses

Statistical analysis title	B_MY: Day 1 (C:AB)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(C_7.5QIV+0MF59:A_7.5TIV +0MF59 + B_15TIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[396]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[396] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (D:AB)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(D_15 QIV + 0MF59:A_7.5TIV +0MF59 + B_15TIV+0MF59)

Comparison groups	D_15QIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority[397]
P-value	= 0.5
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.03

Notes:

[397] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (F:E)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(F_7.5 aQIV+ ⅛MF59:E_7.5 aTIV+ ⅛MF59)

Comparison groups	E_7.5aTIV+⅛MF59 v F_7.5aQIV+⅛MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	superiority[398]
P-value	= 0.065
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[398] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (I:GH)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day1.
(I_7.5 aQIV+ ¼MF59:G_7.5 aTIV+ ¼MF59 + H_15 aTIV + ¼MF59)

Comparison groups	I_7.5aQIV+¼MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority[399]
P-value	= 0.065
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.04

Notes:

[399] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (J:GH)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(J_15 aQIV + ¼MF59:G_7.5 aTIV+ ¼MF59 + H_15 aTIV + ¼MF59)

Comparison groups	J_15aQIV+¼MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority[400]
P-value	= 0.059
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.07

Notes:

[400] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (M:KL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(M_7.5 aQIV+ ½MF59:K_7.5 aTIV+ ½MF59 + L_15 aTIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority[401]
P-value	= 0.79
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.95
upper limit	1.02

Notes:

[401] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (N:KL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15µg TIV for Day 1.
(N_15 aQIV + ½MF59:K_7.5 aTIV+ ½MF59 + L_15 aTIV+ ½MF59)

Comparison groups	N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority[402]
P-value	= 0.8
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.95
upper limit	1.02

Notes:

[402] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 1 (P:O)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(P_15 aQIV+fullMF59:O_15 aTIV + fullMF59)

Comparison groups	P_15aQIV+fullMF59 v O_15aTIV+fullMF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	superiority[403]
P-value	= 0.063
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.08

Notes:

[403] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (C:AB)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29/Day 50 .
(C_7.5QIV+0MF59:A_7.5TIV +0MF59 + B_15TIV+0MF59)

Comparison groups	C_7.5QIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority[404]
P-value	= 0.008
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.13
upper limit	3.14

Notes:

[404] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (D:AB)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(D_15 QIV + 0MF59:A_7.5TIV +0MF59 + B_15TIV+0MF59)

Comparison groups	D_15QIV+0MF59 v A_7.5TIV+0MF59 + B_15TIV+0MF59
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority[405]
P-value	= 0.018
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.04
upper limit	2.74

Notes:

[405] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (F:E)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29/Day 50.
(F_7.5 aQIV+ ⅛MF59:E_7.5 aTIV+ ⅛MF59)

Comparison groups	F_7.5aQIV+⅛MF59 v E_7.5aTIV+⅛MF59
Number of subjects included in analysis	44
Analysis specification	Pre-specified
Analysis type	superiority[406]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	4.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.23
upper limit	7.43

Notes:

[406] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (I:GH)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29/Day 50.
(I_7.5 aQIV+ ¼MF59:G_7.5 aTIV+ ¼MF59 + H_15 aTIV + ¼MF59)

Comparison groups	I_7.5aQIV+¼MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority[407]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	5.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.28
upper limit	9.48

Notes:

[407] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (J:GH)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29/Day 50 .
(J_15 aQIV + ¼MF59:G_7.5 aTIV+ ¼MF59 + H_15 aTIV + ¼MF59)

Comparison groups	J_15aQIV+¼MF59 v G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59

Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority[408]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.2
upper limit	9.45

Notes:

[408] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (M:KL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29/Day 50.
(M_7.5 aQIV+ ½MF59:K_7.5 aTIV+ ½MF59 + L_15 aTIV+ ½MF59)

Comparison groups	M_7.5aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority[409]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	4.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.99
upper limit	8.3

Notes:

[409] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (N:KL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15µg TIV for Day 29/Day 50.
(N_15 aQIV + ½MF59:K_7.5 aTIV+ ½MF59 + L_15 aTIV+ ½MF59)

Comparison groups	N_15aQIV+½MF59 v K_7.5aTIV+½MF59 + L_15aTIV+½MF59
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority[410]
P-value	< 0.001
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	4.96

Confidence interval	
level	95 %
sides	2-sided
lower limit	3.02
upper limit	8.13

Notes:

[410] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_MY: Day 29/Day 50 (P:O)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29/Day 50.
(P_15 aQIV+fullMF59:O_15 aTIV + fullMF59)

Comparison groups	P_15aQIV+fullMF59 v O_15aTIV+fullMF59
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	superiority[411]
P-value	= 0.007
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	2.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.17
upper limit	3.67

Notes:

[411] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Primary: 12. Assessing Geometric Mean Titer (GMTs) to evaluate whether the addition of a second influenza B strain (Malaysia) to a TIV (QIV) increases cross-reactive antibody responses to A/H3N2, A/H1N1 and the first influenza B strain (Florida).

End point title	12. Assessing Geometric Mean Titer (GMTs) to evaluate whether the addition of a second influenza B strain (Malaysia) to a TIV (QIV) increases cross-reactive antibody responses to A/H3N2, A/H1N1 and the first influenza B strain (Florida).

End point description:

To assess immunogenicity in terms of GMTs against strains A/H1N1, A/H3N2 and B/Florida 06 for the combined pediatric QIV group (i.e., all study vaccine groups with 7.5µg TIV formulated with a second B strain, B/Malaysia 04), were compared with GMTs against the same strains for the combined pediatric TIV group (i.e. all study vaccine groups with 7.5µg TIV formulated without the second B strain) and GMTs for the combined non-pediatric (15µg) QIV groups were compared with those from the corresponding TIV groups.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

End point values	AEGK	BHL	CFIM	DJN
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	97	61	89	77
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	7.81 (6.31 to 9.67)	7.27 (5.56 to 9.52)	7.35 (5.88 to 9.19)	7.26 (5.72 to 9.23)
A/H1N1 (Day 29) (N=77,52,73,61)	72 (45 to 114)	59 (34 to 104)	64 (40 to 103)	71 (42 to 119)
A/H1N1 (Day 50) (N=74,52,73,59)	287 (198 to 416)	255 (164 to 397)	304 (209 to 441)	298 (197 to 451)
A/H3N2 (Day 1)	9.65 (7.49 to 12)	6.64 (4.83 to 9.14)	6.99 (5.37 to 9.1)	7.07 (5.32 to 9.39)
A/H3N2 (Day 29) (N=77,52,73,61)	102 (68 to 151)	65 (41 to 106)	53 (36 to 80)	45 (29 to 70)
A/H3N2 (Day 50) (N=74,52,73,59)	418 (297 to 589)	293 (195 to 442)	255 (180 to 360)	191 (130 to 280)
B_FL (Day 1)	5.77 (5.33 to 6.24)	5.23 (4.74 to 5.78)	6.05 (5.58 to 6.57)	5.37 (4.92 to 5.87)
B_FL (Day 29) (N=77,52,73,61)	11 (7.96 to 14)	9.54 (6.77 to 13)	9.14 (6.84 to 12)	10 (7.45 to 14)
B_FL (Day 50) (N=74,52,73,59)	49 (36 to 66)	37 (26 to 53)	41 (30 to 55)	40 (29 to 56)

Statistical analyses

Statistical analysis title	A/H1N1:Day 1 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(C_7.5QIV+0MF59 + F_7.5aQIV+⅛MF59 + I_7.5aQIV+¼MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59+ E_7.5aTIV+⅛MF59 + G_7.5aTIV+¼MF59 + K_7.5aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[412]
P-value	= 0.7
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.28

Notes:

[412] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1:Day 1 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.

(D_15aQIV+0MF59 + J_15aQIV+¼MF59 + N_15aQIV+½MF59 : B_15TIV+0MF59 + H_15aTIV+¼MF59 + L_15aTIV+½MF59)

Comparison groups	BHL v DJN
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[413]
P-value	= 0.99
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.43

Notes:

[413] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for day 1.
(C_7.5QIV+0MF59 + F_7.5aQIV+⅛MF59 + I_7.5aQIV+¼MF59 + M_7.5aQIV+½MF59 : A_7.5TIV+0MF59+ E_7.5aTIV+⅛MF59 + G_7.5aTIV+¼MF59 + K_7.5aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[414]
P-value	= 0.084
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.04

Notes:

[414] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2: Day 1 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15µg TIV for day 1.
(D_15aQIV+0MF59 + J_15aQIV+¼MF59 + N_15aQIV+½MF59 : B_15TIV+0MF59 + H_15aTIV+¼MF59 + L_15aTIV+½MF59)

Comparison groups	BHL v DJN

Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[415]
P-value	= 0.77
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.63

Notes:

[415] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL:Day 1 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(C_7.5 QIV+0MF59 + F_7.5 aQIV+⅛MF59 + I_7.5 aQIV+¼MF59 + M_7.5 aQIV+½MF59 : A_7.5 TIV+0MF59+ E_7.5 aTIV+⅛MF59 + G_7.5 aTIV+¼MF59 + K_7.5 aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[416]
P-value	= 0.41
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	1.17

Notes:

[416] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL:Day 1 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 1.
(D_15 aQIV + 0MF59 + J_15 aQIV + ¼MF59 + N_15 aQIV + ½MF59 : B_15 TIV + 0MF59 + H_15 aTIV + ¼MF59 + L_15 aTIV+ ½MF59)

Comparison groups	BHL v DJN
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[417]
P-value	= 0.69
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.17

Notes:

[417] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1:Day 29 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29.
(C_7.5 QIV+0MF59 + F_7.5 aQIV+⅛MF59 + I_7.5 aQIV+¼MF59 + M_7.5 aQIV+½MF59 : A_7.5 TIV+0MF59+ E_7.5 aTIV+⅛MF59 + G_7.5 aTIV+¼MF59 + K_7.5 aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[418]
P-value	= 0.74
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.46
upper limit	1.74

Notes:

[418] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1:Day 29 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29.
(D_15 aQIV + 0MF59 + J_15 aQIV + ¼MF59 + N_15 aQIV + ½MF59 : B_15 TIV + 0MF59 + H_15 aTIV + ¼MF59 + L_15 aTIV+ ½MF59)

Comparison groups	BHL v DJN
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[419]
P-value	= 0.64
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	2.58

Notes:

[419] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2:Day 29 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29.
(C_7.5 QIV+0MF59 + F_7.5 aQIV+⅛MF59 + I_7.5 aQIV+¼MF59 + M_7.5 aQIV+½MF59 : A_7.5 TIV+0MF59+ E_7.5 aTIV+⅛MF59 + G_7.5 aTIV+¼MF59 + K_7.5 aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[420]
P-value	= 0.026
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	0.93

Notes:

[420] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2:Day 29 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29.
(D_15 aQIV + 0MF59 + J_15 aQIV + ¼MF59 + N_15 aQIV + ½MF59 : B_15 TIV + 0MF59 + H_15 aTIV + ¼MF59 + L_15 aTIV+ ½MF59)

Comparison groups	BHL v DJN
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[421]
P-value	= 0.25
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.36
upper limit	1.32

Notes:

[421] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL:Day 29 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg

TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29.
(C_7.5 QIV+0MF59 + F_7.5 aQIV+⅛MF59 + I_7.5 aQIV+¼MF59 + M_7.5 aQIV+½MF59 : A_7.5 TIV+0MF59+ E_7.5 aTIV+⅛MF59 + G_7.5 aTIV+¼MF59 + K_7.5 aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[422]
P-value	= 0.48
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	1.3

Notes:

[422] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL: Day 29 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg/15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 29.
(D_15QIV+0MF59 + J_15aQIV+¼MF59 + N_15aQIV+½MF59 : B_15TIV+0MF59 + H_15aTIV+¼MF59 + L_15aTIV+½MF59)

Comparison groups	BHL v DJN
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[423]
P-value	= 0.77
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.71

Notes:

[423] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1:Day 50 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 50.
(C_7.5 QIV+0MF59 + F_7.5 aQIV+⅛MF59 + I_7.5 aQIV+¼MF59 + M_7.5 aQIV+½MF59 : A_7.5 TIV+0MF59+ E_7.5 aTIV+⅛MF59 + G_7.5 aTIV+¼MF59 + K_7.5 aTIV+½MF59)

Comparison groups	CFIM v AEGK

Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[424]
P-value	= 0.84
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	1.79

Notes:

[424] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H1N1:Day 50 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 50.
(D_15 aQIV + 0MF59 + J_15 aQIV + ¼MF59 + N_15 aQIV + ½MF59 : B_15 TIV + 0MF59 + H_15 aTIV + ¼MF59 + L_15 aTIV+ ½MF59)

Comparison groups	DJN v BHL
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[425]
P-value	= 0.61
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	2.14

Notes:

[425] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2:Day 50 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 50.
(C_7.5 QIV+0MF59 + F_7.5 aQIV+⅛MF59 + I_7.5 aQIV+¼MF59 + M_7.5 aQIV+½MF59 : A_7.5 TIV+0MF59+ E_7.5 aTIV+⅛MF59 + G_7.5 aTIV+¼MF59 + K_7.5 aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[426]
P-value	= 0.046
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.61

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	0.99

Notes:

[426] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	A/H3N2:Day 50 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 50.
(D_15 aQIV + 0MF59 + J_15 aQIV + ¼MF59 + N_15 aQIV + ½MF59 : B_15 TIV + 0MF59 + H_15 aTIV + ¼MF59 + L_15 aTIV+ ½MF59)

Comparison groups	BHL v DJN
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[427]
P-value	= 0.13
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	1.14

Notes:

[427] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B-FL:Day 50 (CFIM: AEGK)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 50.
(C_7.5 QIV+0MF59 + F_7.5 aQIV+⅛MF59 + I_7.5 aQIV+¼MF59 + M_7.5 aQIV+½MF59 : A_7.5 TIV+0MF59+ E_7.5 aTIV+⅛MF59 + G_7.5 aTIV+¼MF59 + K_7.5 aTIV+½MF59)

Comparison groups	CFIM v AEGK
Number of subjects included in analysis	186
Analysis specification	Pre-specified
Analysis type	superiority[428]
P-value	= 0.42
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.28

Notes:

[428] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Statistical analysis title	B_FL:Day 50 (DJN:BHL)

Statistical analysis description:

To evaluate the superiority of GMTs against the B strain (Malaysia), the 7.5µg / 15µg TIV/QIV/aTIV/aQIV groups of identical MF59 content pooled and compared with the non adjuvanted 7.5µg and 15 µg TIV for Day 50.
(D_15 aQIV + 0MF59 + J_15 aQIV + ¼MF59 + N_15 aQIV + ½MF59 : B_15 TIV + 0MF59 + H_15 aTIV + ¼MF59 + L_15 aTIV+ ½MF59)

Comparison groups	BHL v DJN
Number of subjects included in analysis	138
Analysis specification	Pre-specified
Analysis type	superiority[429]
P-value	= 0.71
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.78

Notes:

[429] - Superiority was to be shown if the lower margin of the 95% confidence interval (CI) was >1.

Primary: 13. Assessing Geometric Mean Titer (GMTs) to evaluate whether increases in antigen dose in TIV increases cross-reactive antibody responses to the second influenza B strain.

End point title	13. Assessing Geometric Mean Titer (GMTs) to evaluate whether increases in antigen dose in TIV increases cross-reactive antibody responses to the second influenza B strain.

End point description:

To assess immunogenicity in terms of GMTs to test for cross-reactivity of 7.5µg and 15µg TIV to the second B strain, the GMT against the second B-strain (B/Malaysia04Ba) in the groups receiving 7.5µg TIV formulated with ½, ¼, and 0 MF59 were combined and compared with GMTs for the combined 15µg TIV formulated with ½, ¼, and 0 MF59.
The 7.5µg TIV+⅛ MF59 and the 15µg TIV+full MF59 groups were excluded from this analysis as the corresponding antigen-adjuvant combinations (i.e.,7.5µgTIV + full MF59 and 15µg TIV + ⅛ MF59) were not used in this study.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1 and Day 50

End point values	BHL	AGK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	61	74		
Units: Titers				
geometric mean (confidence interval 95%)				
B_MY (Day 1)	5 (4.92 to 5.08)	5.05 (4.98 to 5.12)		
B_MY (Day 50) (N=52,56)	9.87 (7.82 to 12)	9.17 (7.33 to 11)		

Statistical analyses

Statistical analysis title	Ratio of GMTs BHL / AGK

Statistical analysis description:

Assessing the crossreactivity of the 7.5µg and 15µg TIV to the second B strain.(B_15 TIV + 0MF59 +H_15 aTIV + ¼MF59 + L_15 aTIV+ ½MF59 : A_7.5 TIV + 0MF59 + G_7.5 aTIV+ ¼MF59 + K_7.5 aTIV+ ½MF59)

Comparison groups	BHL v AGK
Number of subjects included in analysis	135
Analysis specification	Pre-specified
Analysis type	other[430]
P-value	= 0.37
Method	ANOVA
Parameter estimate	Ratio of GMTs
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.01

Notes:

[430] - Evaluating whether increase in antigen dose in TIV increases crossreactive antibody responses to the second influenza B strain.

Primary: 14. GMTs to assess the immunogenicity of the study vaccine formulations according to the EMEA recommendations (CPMP/BWP/214/96).

End point title	14. GMTs to assess the immunogenicity of the study vaccine formulations according to the EMEA recommendations (CPMP/BWP/214/96).[431][432]

End point description:

To assess the immunogenicity of study vaccine formulations in terms of GMTs for various vaccine group for Homologous A/H1N1,A/H3N2, and First Influenza B strains After Each Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 1, Day 29 and Day 50

Notes:

[431] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[432] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	Q_7.5cTIV+0MF59	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	26	49	49	44
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	9.74 (6.39 to 15)	6.4 (4.71 to 8.71)	6.54 (4.81 to 8.89)	8.15 (5.89 to 11)
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37,36)	42 (20 to 87)	14 (7.74 to 24)	12 (7.18 to 21)	109 (61 to 194)
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36,0)	261 (157 to 437)	57 (37 to 85)	69 (47 to 102)	533 (351 to 810)
A/H3N2 (Day 1)	5 (3.14 to 7.97)	7.38 (5.25 to 10)	7.22 (5.14 to 10)	7.96 (5.56 to 11)
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37,36)	22 (12 to 38)	19 (12 to 29)	12 (7.58 to 18)	91 (58 to 144)
A/H3N2 (Day 50) (N=24,37,42,36,34,33,40,36,0)	133 (83 to 211)	73 (50 to 106)	60 (42 to 86)	518 (354 to 758)
B_FL (Day 1)	5.87 (5.03 to 6.84)	5.37 (4.8 to 6)	5.29 (4.73 to 5.92)	6.23 (5.54 to 7.01)
B_FL (Day 29) (N=23,37,43,37,35,33,41,37,36)	11 (6.41 to 18)	8.45 (5.61 to 13)	6.74 (4.61 to 9.85)	9.37 (6.22 to 14)
B_FL (Day 50) (N=24,37,42,36,34,33,40,36,0)	24 (16 to 36)	13 (9.45 to 18)	11 (7.98 to 15)	61 (43 to 84)

End point values	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59	H_15aTIV+¼MF59 + J_15aQIV+¼MF59	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59	L_15aTIV+½MF59 + N_15aQIV+½MF59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	44	44	49	45
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	8.41 (6.08 to 12)	7.83 (5.67 to 11)	7.7 (5.66 to 10)	7.58 (5.5 to 10)
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37,36)	118 (65 to 213)	149 (81 to 273)	118 (68 to 204)	220 (124 to 391)
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36,0)	481 (313 to 740)	576 (372 to 892)	529 (356 to 787)	718 (473 to 1092)
A/H3N2 (Day 1)	9.54 (6.67 to 14)	6.8 (4.75 to 9.73)	8.44 (6.01 to 12)	6.6 (4.63 to 9.4)
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37,36)	114 (72 to 182)	112 (69 to 181)	150 (97 to 230)	163 (104 to 257)
A/H3N2 (Day 50) (N=24,37,42,36,34,33,40,36,0)	496 (335 to 734)	503 (338 to 748)	608 (423 to 872)	559 (382 to 819)
B_FL (Day 1)	6.33 (5.63 to 7.13)	5.16 (4.59 to 5.81)	5.8 (5.19 to 6.49)	5.48 (4.88 to 6.16)
B_FL (Day 29) (N=23,37,43,37,35,33,41,37,36)	13 (8.24 to 19)	8.45 (5.48 to 13)	9.59 (6.5 to 14)	18 (12 to 27)

B_FL (Day 50) (N=24,37,42,36,34,33,40,36,0)	61 (43 to 86)	69 (49 to 98)	81 (59 to 112)	101 (72 to 141)

End point values	O_15aTIV+full MF59 + P_15aQIV+full MF59			
Subject group type	Subject analysis set			
Number of subjects analysed	45			
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 1)	7.4 (5.37 to 10)			
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37,36)	196 (109 to 351)			
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36,0)	0 (0 to 0)			
A/H3N2 (Day 1)	6.7 (4.7 to 9.55)			
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37,36)	165 (104 to 261)			
A/H3N2 (Day 50) (N=24,37,42,36,34,33,40,36,0)	0 (0 to 0)			
B_FL (Day 1)	5.57 (4.96 to 6.26)			
B_FL (Day 29) (N=23,37,43,37,35,33,41,37,36)	15 (9.61 to 22)			
B_FL (Day 50) (N=24,37,42,36,34,33,40,36,0)	0 (0 to 0)			

Statistical analyses

No statistical analyses for this end point

Primary: 15. Geometric Mean Ratios (GMRs) to assess the immunogenicity of the study vaccine formulations according to the EMEA recommendations (CPMP/BWP/214/96).

End point title	15. Geometric Mean Ratios (GMRs) to assess the immunogenicity of the study vaccine formulations according to the EMEA recommendations (CPMP/BWP/214/96).[433][434]

End point description:

To assess the immunogenicity of study vaccine formulations in terms of GMRs for various vaccine group for Homologous A/H1N1,A/H3N2, and First Influenza B strains After Each Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day29/ Day1 and Day50/ Day1

Notes:

[433] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[434] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	Q_7.5cTIV+0MF59	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	24	37	43	36
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	4.44 (2.82 to 7)	1.98 (1.39 to 2.83)	1.83 (1.31 to 2.55)	14 (9.82 to 20)
A/H1N1 (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	25 (17 to 39)	8.15 (5.79 to 11)	10 (7.43 to 14)	72 (51 to 103)
A/H3N2 (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	4.31 (2.87 to 6.49)	2.22 (1.61 to 3.06)	1.91 (1.41 to 2.57)	10 (7.48 to 14)
A/H3N2 (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	27 (16 to 43)	8.7 (5.9 to 13)	9.91 (6.88 to 14)	61 (41 to 91)
B_FL (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	1.8 (1.19 to 2.73)	1.54 (1.11 to 2.14)	1.28 (0.95 to 1.74)	1.73 (1.24 to 2.41)
B_FL (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	4.06 (2.8 to 5.89)	2.39 (1.77 to 3.22)	2.07 (1.56 to 2.74)	11 (8.15 to 15)

End point values	G_7.5aTIV+¼MF59 + I_7.5aQIV+¼MF59	H_15aTIV+¼MF59 + J_15aQIV+¼MF59	K_7.5aTIV+½MF59 + M_7.5aQIV+½MF59	L_15aTIV+½MF59 + N_15aQIV+½MF59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	34	33	41	36
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	14 (9.45 to 20)	19 (13 to 27)	16 (11 to 23)	25 (18 to 37)
A/H1N1 (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	61 (43 to 88)	65 (45 to 93)	78 (56 to 109)	84 (59 to 120)
A/H3N2 (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	13 (9.52 to 19)	17 (12 to 24)	18 (13 to 24)	21 (15 to 30)
A/H3N2 (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	57 (38 to 86)	77 (51 to 117)	72 (50 to 105)	76 (51 to 114)
B_FL (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	2.06 (1.46 to 2.9)	1.62 (1.15 to 2.29)	1.67 (1.23 to 2.29)	3.3 (2.37 to 4.6)
B_FL (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	10 (7.42 to 14)	13 (9.64 to 18)	14 (11 to 19)	18 (13 to 25)

End point values	O_15aTIV+fullMF59 + P_15aQIV+fullMF59			

Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: Titers				
geometric mean (confidence interval 95%)				
A/H1N1 (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	24 (17 to 34)			
A/H1N1 (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	0 (0 to 0)			
A/H3N2 (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	23 (16 to 32)			
A/H3N2 (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	0 (0 to 0)			
B_FL (Day29/Day1) (N=23,37,43,36,34,33,41,36,36)	2.54 (1.82 to 3.55)			
B_FL (Day50/Day1) (N=24,37,42,35,33,33,40,35,0)	0 (0 to 0)			

Statistical analyses

No statistical analyses for this end point

Primary: 16. Percentage of Subjects With HI Titers >= 1:40 for Homologous A/H1N1, A/H3N2, and First Influenza B Homologous Strains After Each Vaccination

End point title	16. Percentage of Subjects With HI Titers >= 1:40 for Homologous A/H1N1, A/H3N2, and First Influenza B Homologous Strains After Each Vaccination[435][436]

End point description:

To assess the immunogenicity in terms of Percentage of subjects with HI Titers >= 1:40 increase for various vaccine group for Homologous A/H1N1,A/H3N2, and First Influenza B strains After Each Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).
Seroconversion is defined as negative pre-vaccination serum (i.e., HI titer <10) and post-vaccination HI titer ≥ 40;
Significant increase is defined at least a 4-fold increase from non-negative (≥ 10) pre-vaccination HI titer.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 29 and Day 50

Notes:

[435] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[436] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	Q_7.5cTIV+0MF59	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	24	37	43	37
Units: Percentage of Subjects				

number (confidence interval 95%)				
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37,36)	43 (23 to 66)	16 (6 to 32)	21 (10 to 36)	81 (65 to 92)
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36,0)	96 (79 to 100)	65 (47 to 80)	79 (63 to 90)	97 (85 to 100)
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37,36)	35 (16 to 57)	30 (16 to 47)	12 (4 to 25)	84 (68 to 94)
A/H3N2 (Day 50) (N=24,37,42,36,34,33,40,36,0)	92 (73 to 99)	70 (53 to 84)	71 (55 to 84)	100 (90 to 100)
B_FL (Day 29) (N=23,37,43,37,35,33,41,37,36)	22 (7 to 44)	14 (5 to 29)	7 (1 to 19)	11 (3 to 25)
B_FL (Day 50) (N=24,37,42,36,34,33,40,36,0)	42 (22 to 63)	19 (8 to 35)	12 (4 to 26)	83 (67 to 94)

End point values	G_7.5aTIV+¼ MF59 + I_7.5aQIV+¼M F59	H_15aTIV+¼M F59 + J_15aQIV+¼M F59	K_7.5aTIV+½ MF59 + M_7.5aQIV+½ MF59	L_15aTIV+½M F59 + N_15aQIV+½M F59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	35	33	41	37
Units: Percentage of Subjects				
number (confidence interval 95%)				
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37,36)	77 (60 to 90)	85 (68 to 95)	88 (74 to 96)	95 (82 to 99)
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36,0)	100 (90 to 100)	100 (89 to 100)	100 (91 to 100)	100 (90 to 100)
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37,36)	89 (73 to 97)	88 (72 to 97)	98 (87 to 100)	92 (78 to 98)
A/H3N2 (Day 50) (N=24,37,42,36,34,33,40,36,0)	100 (90 to 100)	100 (89 to 100)	100 (91 to 100)	100 (90 to 100)
B_FL (Day 29) (N=23,37,43,37,35,33,41,37,36)	14 (5 to 30)	9 (2 to 24)	12 (4 to 26)	22 (10 to 38)
B_FL (Day 50) (N=24,37,42,36,34,33,40,36,0)	88 (73 to 94)	85 (68 to 95)	90 (76 to 97)	97 (85 to 100)

End point values	O_15aTIV+full MF59 + P_15aQIV+full MF59			
Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: Percentage of Subjects				
number (confidence interval 95%)				
A/H1N1 (Day 29) (N=23,37,43,37,35,33,41,37,36)	94 (81 to 99)			
A/H1N1 (Day 50) (N=24,37,42,36,34,33,40,36,0)	0 (0 to 0)			
A/H3N2 (Day 29) (N=23,37,43,37,35,33,41,37,36)	97 (85 to 100)			
A/H3N2 (Day 50) (N=24,37,42,36,34,33,40,36,0)	0 (0 to 0)			
B_FL (Day 29) (N=23,37,43,37,35,33,41,37,36)	17 (6 to 33)			

B_FL (Day 50) (N=24,37,42,36,34,33,40,36,0)	0 (0 to 0)			

Statistical analyses

No statistical analyses for this end point

Primary: 17. Percentage of subjects with Seroconversion and significant increase for Homologous A/H1N1, A/H3N2, and First Influenza B Homologous Strains After Each Vaccination

End point title	17. Percentage of subjects with Seroconversion and significant increase for Homologous A/H1N1, A/H3N2, and First Influenza B Homologous Strains After Each Vaccination[437][438]

End point description:

To assess the immunogenicity in terms of Percentage of subjects with Seroconversion and significant increase for various vaccine group for Homologous A/H1N1,A/H3N2, and First Influenza B strains After Each Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).
Seroconversion is defined as negative pre-vaccination serum (i.e., HI titer <10) and post-vaccination HI titer ≥ 40;
Significant increase is defined at least a 4-fold increase from non-negative (≥ 10) pre-vaccination HI titer.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 29 and Day 50

Notes:

[437] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[438] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	Q_7.5cTIV+0MF59	A_7.5TIV+0MF59 + C_7.5QIV+0MF59	B_15TIV+0MF59 + D_15QIV+0MF59	E_7.5aTIV+⅛MF59 + F_7.5aQIV+⅛MF59
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	24	37	43	36
Units: Percentage of subjects				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 29) (N= 23,37,43,36,34,33,41,36,36)	39 (20 to 61)	14 (5 to 29)	21 (10 to 36)	81 (64 to 95)
A/H1N1 (Day 50) (N= 24,37,42,35,33,33,40,35,0)	96 (79 to 100)	62 (45 to 78)	79 (63 to 90)	97 (85 to 100)
A/H3N2 (Day 29) (N= 23,37,43,36,34,33,41,36,36)	35 (16 to 57)	22 (10 to 38)	9 (3 to 22)	81 (64 to 92)
A/H3N2 (Day 50) (N= 24,37,42,35,33,33,40,35,0)	92 (73 to 99)	62 (45 to 78)	71 (55 to 84)	97 (85 to 100)
B_FL (Day 29) (N= 23,37,43,36,34,33,41,36,36)	22 (7 to 44)	14 (5 to 29)	7 (1 to 19)	11 (3 to 26)

B_FL (Day 50) (N= 24,37,42,35,33,33,40,35,0)	42 (22 to 63)	19 (8 to 35)	12 (4 to 26)	83 (66 to 93)

End point values	G_7.5aTIV+¼ MF59 + I_7.5aQIV+¼M F59	H_15aTIV+¼M F59 + J_15aQIV+¼M F59	K_7.5aTIV+½ MF59 + M_7.5aQIV+½ MF59	L_15aTIV+½M F59 + N_15aQIV+½M F59
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	34	33	41	36
Units: Percentage of subjects				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 29) (N= 23,37,43,36,34,33,41,36,36)	79 (62 to 91)	85 (68 to 95)	88 (74 to 96)	94 (81 to 99)
A/H1N1 (Day 50) (N= 24,37,42,35,33,33,40,35,0)	100 (89 to 100)	100 (89 to 100)	100 (91 to 100)	100 (90 to 100)
A/H3N2 (Day 29) (N= 23,37,43,36,34,33,41,36,36)	85 (69 to 95)	88 (72 to 97)	98 (87 to 100)	92 (78 to 98)
A/H3N2 (Day 50) (N= 24,37,42,35,33,33,40,35,0)	94 (80 to 99)	100 (89 to 100)	100 (91 to 100)	100 (90 to 100)
B_FL (Day 29) (N= 23,37,43,36,34,33,41,36,36)	15 (5 to 31)	9 (2 to 24)	12 (4 to 26)	22 (10 to 39)
B_FL (Day 50) (N= 24,37,42,35,33,33,40,35,0)	88 (72 to 97)	85 (68 to 95)	90 (76 to 97)	97 (85 to 100)

End point values	O_15aTIV+full MF59 + P_15aQIV+full MF59			
Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: Percentage of subjects				
geometric mean (confidence interval 95%)				
A/H1N1 (Day 29) (N= 23,37,43,36,34,33,41,36,36)	94 (81 to 99)			
A/H1N1 (Day 50) (N= 24,37,42,35,33,33,40,35,0)	0 (0 to 0)			
A/H3N2 (Day 29) (N= 23,37,43,36,34,33,41,36,36)	94 (81 to 99)			
A/H3N2 (Day 50) (N= 24,37,42,35,33,33,40,35,0)	0 (0 to 0)			
B_FL (Day 29) (N= 23,37,43,36,34,33,41,36,36)	17 (6 to 33)			
B_FL (Day 50) (N= 24,37,42,35,33,33,40,35,0)	0 (0 to 0)			

Statistical analyses

No statistical analyses for this end point

Primary: 18. Assessing Immunogenicity in terms of GMTs of the Study Vaccine Formulations for Homologous second B strain after Each QIV Vaccination

End point title	18. Assessing Immunogenicity in terms of GMTs of the Study Vaccine Formulations for Homologous second B strain after Each QIV Vaccination[439][440]

End point description:

To assess the immunogenicity in terms of GMTs for various vaccine group for Homologous second B strain After Each QIV Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 29/Day 1 and Day 50/Day 1

Notes:

[439] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[440] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	22	24	19
Units: Titers				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,18,18,18,19,21,18,18,40,32,38)	6.39 (4.94 to 8.25)	5 (3.99 to 6.26)	5 (4.01 to 6.23)	6.22 (4.89 to 7.93)
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	11 (7.24 to 16)	9.68 (6.68 to 14)	5.37 (3.8 to 7.59)	10 (6.97 to 15)

End point values	F_7.5aQIV+⅛MF59	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	18	18	19
Units: Titers				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,18,18,18,19,21,18,18,40,32,38)	6.06 (4.73 to 7.77)	5.83 (4.55 to 7.48)	6.55 (5.11 to 8.4)	6.22 (4.89 to 7.93)
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	42 (28 to 63)	63 (43 to 95)	63 (42 to 94)	70 (48 to 104)

End point values	N_15aQIV+½MF59	O_15aTIV+fullMF59	P_15aQIV+fullMF59	A_7.5TIV+0MF59 + B_15TIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	21	18	18	40

Units: Titers				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,18,18,18,19,21,18,18,40,32,38)	7.19 (5.71 to 9.05)	5.4 (4.21 to 6.93)	11 (8.59 to 14)	5 (4.23 to 5.91)
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	70 (48 to 101)	0 (0 to 0)	0 (0 to 0)	5.74 (4.39 to 7.51)

End point values	G_7.5aTIV+¼ MF59 + H_15aTIV+¼MF59	K_7.5aTIV+½ MF59 + L_15aTIV+½MF59		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	32	38		
Units: Titers				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,18,18,18,19,21,18,18,40,32,38)	5.45 (4.52 to 6.57)	5.79 (4.88 to 6.87)		
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	11 (8.44 to 15)	14 (11 to 19)		

Statistical analyses

No statistical analyses for this end point

Primary: 19. Assessing Immunogenicity in terms of GMRs of the Study Vaccine Formulations for Homologous second B strain after Each QIV Vaccination

End point title	19. Assessing Immunogenicity in terms of GMRs of the Study Vaccine Formulations for Homologous second B strain after Each QIV Vaccination[441][442]

End point description:

To assess the immunogenicity in terms of GMRs for various vaccine group for Homologous second B strain After Each QIV Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).

End point type	Primary

End point timeframe:

Day 29/Day 1 and Day 50/Day 1

Notes:

[441] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[442] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	22	24	19
Units: Ratios				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,17,17,18,19,21,18,18,40,32,37)	1.28 (0.99 to 1.64)	1 (0.8 to 1.25)	1 (0.81 to 1.24)	1.24 (0.98 to 1.58)
Day50 (N= 18,21,24,18,17,17,17,19,21,0,0,40,32,35)	2.16 (1.45 to 3.22)	1.94 (1.34 to 2.8)	1.07 (0.76 to 1.52)	2.08 (1.39 to 3.1)

End point values	F_7.5aQIV+⅛MF59	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	17	18	19
Units: Ratios				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,17,17,18,19,21,18,18,40,32,37)	1.18 (0.92 to 1.51)	1.18 (0.92 to 1.51)	1.26 (0.99 to 1.61)	1.24 (0.98 to 1.58)
Day50 (N= 18,21,24,18,17,17,17,19,21,0,0,40,32,35)	8.85 (5.86 to 13)	13 (8.3 to 19)	12 (7.97 to 18)	14 (9.54 to 21)

End point values	N_15aQIV+½MF59	O_15aTIV+fullMF59	P_15aQIV+fullMF59	A_7.5TIV+0MF59 + B_15TIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	21	18	18	40
Units: Ratios				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,17,17,18,19,21,18,18,40,32,37)	1.44 (1.15 to 1.8)	1.08 (0.85 to 1.38)	2.12 (1.66 to 2.7)	1 (0.85 to 1.18)
Day50 (N= 18,21,24,18,17,17,17,19,21,0,0,40,32,35)	14 (9.68 to 20)	0 (0 to 0)	0 (0 to 0)	1.15 (0.88 to 1.5)

End point values	G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59	K_7.5aTIV+½MF59 + L_15aTIV+½MF59		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	32	37		

Units: Ratios				
geometric mean (confidence interval 95%)				
Day29(N=17,22,23,19,17,17,18,19,21,18,18,40,32,37)	1.09 (0.91 to 1.31)	1.14 (0.96 to 1.35)		
Day50 (N= 18,21,24,18,17,17,17,19,21,0,0,40,32,35)	2.28 (1.69 to 3.07)	2.86 (2.14 to 3.81)		

Statistical analyses

No statistical analyses for this end point

Primary: 20. Assessment of Immunogenicity of the Study Vaccine Formulations in terms of Percentage of Subjects with HI titers >=1:40 for Homologous second B strain After Each QIV Vaccination.

End point title	20. Assessment of Immunogenicity of the Study Vaccine Formulations in terms of Percentage of Subjects with HI titers >=1:40 for Homologous second B strain After Each QIV Vaccination.[443][444]

End point description:

To assess the immunogenicity in terms of Percentage of Subjects with HI titers >=1:40 for various vaccine group for Homologous second B strain After Each QIV Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 29 and Day 50

Notes:

[443] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[444] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	22	24	19
Units: Percentage of Subjects				
number (confidence interval 95%)				
Day29(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38)	6 (0 to 27)	0 (0 to 15)	0 (0 to 15)	5 (0 to 26)
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	17 (4 to 41)	14 (3 to 36)	0 (0 to 14)	11 (1 to 35)

End point values	F_7.5aQIV+⅛MF59	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	M_7.5aQIV+½MF59

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	18	18	19
Units: Percentage of Subjects				
number (confidence interval 95%)				
Day29(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38)	0 (0 to 19)	0 (0 to 19)	6 (0 to 27)	0 (0 to 18)
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	72 (47 to 90)	83 (59 to 96)	76 (50 to 93)	79 (54 to 94)

End point values	N_15aQIV+½MF59	O_15aTIV+full MF59	P_15aQIV+full MF59	A_7.5TIV+0MF59 + B_15TIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	21	18	18	40
Units: Percentage of Subjects				
number (confidence interval 95%)				
Day29(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38)	5 (0 to 24)	0 (0 to 19)	17 (4 to 41)	0 (0 to 9)
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	95 (76 to 100)	0 (0 to 0)	0 (0 to 0)	3 (0.063 to 13)

End point values	G_7.5aTIV+¼MF59 + H_15aTIV+¼MF59	K_7.5aTIV+½MF59 + L_15aTIV+½MF59		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	32	38		
Units: Percentage of Subjects				
number (confidence interval 95%)				
Day29(N=18,22,23,19,18,18,18,19,21,18,18,40,32,38)	0 (0 to 11)	0 (0 to 9)		
Day50 (N=18,21,24,18,18,18,17,19,21,0,0,40,	9 (2 to 25)	25 (12 to 42)		

Statistical analyses

No statistical analyses for this end point

Primary: 21. Assessment of Immunogenicity of the Study Vaccine Formulations in terms of Percentage of Subjects with Seroconversion and significant increase for Homologous second B strain After Each QIV Vaccination.

End point title	21. Assessment of Immunogenicity of the Study Vaccine Formulations in terms of Percentage of Subjects with Seroconversion and significant increase for Homologous second B strain After Each QIV Vaccination.[445][446]

End point description:

To assess the immunogenicity in terms of Percentage of Subjects with Seroconversion and significant increase for various vaccine group for Homologous second B strain After Each QIV Vaccination according to the EMEA recommendations (CPMP/BWP/214/96).
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 29 and Day 50

Notes:

[445] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

[446] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analyses for this end point.

End point values	C_7.5QIV+0MF59	D_15QIV+0MF59	F_7.5aQIV+⅛MF59	I_7.5aQIV+¼MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	22	17	17
Units: Percentage of Subjects				
number (confidence interval 95%)				
B_MY (Day 29) (N= 17,22,17,17,18,19,21,18)	6 (0 to 29)	0 (0 to 15)	0 (0 to 20)	0 (0 to 20)
B_MY (Day 50) (N= 18,21,17,17,17,19,21,0)	17 (4 to 41)	14 (3 to 36)	76 (50 to 93)	82 (57 to 96)

End point values	J_15aQIV+¼MF59	M_7.5aQIV+½MF59	N_15aQIV+½MF59	P_15aQIV+fullMF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	19	21	18
Units: Percentage of Subjects				
number (confidence interval 95%)				
B_MY (Day 29) (N= 17,22,17,17,18,19,21,18)	6 (0 to 27)	0 (0 to 18)	5 (0 to 24)	17 (4 to 41)
B_MY (Day 50) (N= 18,21,17,17,17,19,21,0)	76 (50 to 93)	79 (54 to 94)	95 (76 to 100)	0 (0 to 0)

Statistical analyses

No statistical analyses for this end point

Primary: 22. To assess if there is a dose-response trend in immunogenicity responses across all doses of MF59.

End point title	22. To assess if there is a dose-response trend in immunogenicity responses across all doses of MF59.[447]

End point description:

To analyse the dose-response relationship for MF59 using a linear regression analysis with dose and day 50 antibody titers as dependent variables for the three strains and two doses 7.5µg and 15µg/antigen.
The analysis was done on per protocol set.

End point type	Primary

End point timeframe:

Day 50

Notes:

[447] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

End point values	Slope (log10) inc. 95% CI	Slope incl. 95% CI		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	395	395		
Units: Dose-response				
number (confidence interval 95%)				
A/H1N1 (7.5µg)	1.52 (0.97 to 2.07)	33.1 (9.3 to 117.5)		
A/H1N1 (15µg)	2.07 (1.58 to 2.56)	117.5 (38 to 363.1)		
A/H3N2 (7.5µg)	1.48 (0.97 to 1.99)	30.2 (9.3 to 97.7)		
A/H3N2 (15µg)	1.97 (1.51 to 2.43)	93.3 (32.4 to 269.2)		
B_FL (7.5µg)	1.31 (0.91 to 1.72)	20.4 (8.1 to 52.5)		
B_FL (15µg)	1.96 (1.57 to 2.36)	91.2 (37 to 229.1)		
B_MY (0µg)	0.74 (0.44 to 1.05)	5.5 (2.8 to 11.2)		
B_MY (7.5µg)	1.43 (0.83 to 2.03)	26.9 (6.8 to 114.8)		
B_MY (15µg)	1.72 (1.17 to 2.27)	52.5 (14.8 to 186.2)		

Statistical analyses

No statistical analyses for this end point

Primary: 23. Number of subjects with local and systemic solicited adverse events after vaccination with one/two Injections of Trivalent Inactivated Influenza Vaccine (TIV).

End point title	23. Number of subjects with local and systemic solicited adverse events after vaccination with one/two Injections of Trivalent Inactivated Influenza Vaccine (TIV).[448]

End point description:

Assessment of safety on the basis of number of subjects with local and systemic solicited adverse events formulated with non-adjuvant, Eight Dose or Quarted Dose of Adjuvant, Half Dose or Full Dose of Adjuvant.
The analysis was done on safety set.

End point type	Primary

End point timeframe:

Throughout the study

Notes:

[448] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

End point values	A_7.5TIV+0MF59	B_15TIV+0MF59	C_7.5QIV+0MF59	D_15QIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	22	25	28
Units: Number of subjects				
Any Local	13	15	8	13
Injection site Ecchymosis	7	5	5	3
Injection site Erythema	8	7	6	9
Injection site Induration	3	2	1	5
Injection site Swelling	1	2	0	1
Tenderness	5	8	3	6
Any Systemic	17	14	17	20
Sleepiness	6	5	5	6
Diarrhoea	5	6	5	7
Vomiting	2	3	5	4
Irritability	8	8	8	11
Shivering	2	1	2	1
Change eating habits	9	8	5	8
Unusual Crying	8	7	3	9
Fever (>=38.5 C)	5	4	6	5
Body Temp (>40.0 C)	0	1	0	0
Analg Antipy Medic.	4	9	8	11

End point values	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59	F_7.5aQIV+⅛MF59	G_7.5aTIV+¼MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	24	23	23
Units: Number of subjects				
Any Local	15	11	16	13
Injection site Ecchymosis	4	4	4	2
Injection site Erythema	10	8	12	11
Injection site Induration	4	4	6	4
Injection site Swelling	0	2	4	2
Tenderness	8	7	7	5
Any Systemic	16	17	16	11
Sleepiness	9	7	10	2
Diarrhoea	5	7	10	3
Vomiting	3	5	5	0
Irritability	8	11	10	6
Shivering	2	2	2	3
Change eating habits	3	7	9	2
Unusual Crying	4	9	4	5
Fever (>=38.5 C)	3	7	6	3
Body Temp (>40.0 C)	0	1	1	0
Analg Antipy Medic.	5	12	8	4

End point values	H_15aTIV+¼M	I_7.	J_15aQIV+¼M	K_7.

	F59	5aQIV+¼MF59	F59	5aTIV+½MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	24	24	27
Units: Number of subjects				
Any Local	12	11	14	15
Injection site Ecchymosis	2	3	3	6
Injection site Erythema	8	6	11	9
Injection site Induration	5	6	3	6
Injection site Swelling	4	3	5	3
Tenderness	6	8	7	12
Any Systemic	15	14	18	19
Sleepiness	7	3	6	7
Diarrhoea	9	3	6	6
Vomiting	1	3	1	6
Irritability	8	7	11	9
Shivering	2	2	3	1
Change eating habits	7	5	5	10
Unusual Crying	4	4	10	8
Fever (>=38.5 C)	4	8	5	3
Body Temp (>40.0 C)	0	0	0	0
Analg Antipy Medic.	11	9	10	10

End point values	L_15aTIV+½MF59	M_7.5aQIV+½MF59	N_15aQIV+½MF59	O_15aTIV+fullMF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	22	25	26
Units: Number of subjects				
Any Local	14	10	18	13
Injection site Ecchymosis	7	2	2	1
Injection site Erythema	10	7	13	8
Injection site Induration	7	3	6	6
Injection site Swelling	4	0	6	0
Tenderness	7	5	9	7
Any Systemic	19	18	19	14
Sleepiness	5	7	7	6
Diarrhoea	5	7	8	6
Vomiting	4	2	5	2
Irritability	12	10	9	6
Shivering	2	2	1	0
Change eating habits	9	7	6	0
Unusual Crying	11	10	7	4
Fever (>=38.5 C)	4	6	3	2
Body Temp (>40.0 C)	0	0	0	0
Analg Antipy Medic.	12	13	9	7

End point values	P_15aQIV+fullMF59			

Subject group type	Reporting group			
Number of subjects analysed	22			
Units: Number of subjects				
Any Local	8			
Injection site Ecchymosis	2			
Injection site Erythema	3			
Injection site Induration	2			
Injection site Swelling	2			
Tenderness	4			
Any Systemic	12			
Sleepiness	4			
Diarrhoea	5			
Vomiting	1			
Irritability	5			
Shivering	1			
Change eating habits	5			
Unusual Crying	6			
Fever (>=38.5 C)	3			
Body Temp (>40.0 C)	0			
Analg Antipy Medic.	6			

Statistical analyses

No statistical analyses for this end point

Primary: 24. Number of subjects with unsolicited adverse events after vaccination with one/two Injections of Trivalent Inactivated Influenza Vaccine (TIV).

End point title	24. Number of subjects with unsolicited adverse events after vaccination with one/two Injections of Trivalent Inactivated Influenza Vaccine (TIV).[449]

End point description:

Assessment of safety on the basis of number of subjects unsolicited adverse events formulated with non-adjuvant, Eight Dose or Quarter Dose of Adjuvant, Half Dose or Full Dose of Adjuvant.
The analysis was done on safety set.

End point type	Primary

End point timeframe:

Throughout the study

Notes:

[449] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

End point values	A_7.5TIV+0MF59	B_15TIV+0MF59	C_7.5QIV+0MF59	D_15QIV+0MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	22	25	28
Units: Number of subjects				
Any AEs	21	18	23	20
At least possibly related AEs	5	8	1	5
Serious AEs	0	0	1	1
At least possibly related SAEs	0	0	0	0

AEs leading to discontinuation	0	0	0	1

End point values	Q_7.5cTIV+0MF59	E_7.5aTIV+⅛MF59	F_7.5aQIV+⅛MF59	G_7.5aTIV+¼MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	24	23	23
Units: Number of subjects				
Any AEs	19	23	15	19
At least possibly related AEs	5	5	5	6
Serious AEs	1	1	0	0
At least possibly related SAEs	0	0	0	0
AEs leading to discontinuation	0	0	0	0

End point values	H_15aTIV+¼MF59	I_7.5aQIV+¼MF59	J_15aQIV+¼MF59	K_7.5aTIV+½MF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	24	24	27
Units: Number of subjects				
Any AEs	17	18	19	24
At least possibly related AEs	4	2	7	3
Serious AEs	0	0	1	0
At least possibly related SAEs	0	0	0	0
AEs leading to discontinuation	0	0	0	0

End point values	L_15aTIV+½MF59	M_7.5aQIV+½MF59	N_15aQIV+½MF59	O_15aTIV+fullMF59
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	22	25	26
Units: Number of subjects				
Any AEs	20	19	22	15
At least possibly related AEs	3	7	5	3
Serious AEs	2	1	1	0
At least possibly related SAEs	0	0	0	0
AEs leading to discontinuation	0	0	0	0

End point values	P_15aQIV+fullMF59			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: Number of subjects				
Any AEs	20			
At least possibly related AEs	7			
Serious AEs	0			

At least possibly related SAEs	0			
AEs leading to discontinuation	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Throughout the study.

Adverse event reporting additional description:

Number and percentage of children with at least one adverse event or at least one serious adverse event or one adverse event leading to medical visit/consultation or to withdrawal from the study throughout the study (day 50 for groups A through N and group Q; day 29 for groups O and P).

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	11.1

Reporting groups

Reporting group title	A_7.5 TIV+0MF59

Reporting group description:

Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 7.5µg per antigen) on day 1 and day 29.

Reporting group title	B_15 TIV+0MF59

Reporting group description:

Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (TIV - 15µg per antigen) on day 1 and day 29.

Reporting group title	C_7.5 QIV+0MF59

Reporting group description:

Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 7.5µg per antigen) on day 1 and day 29.

Reporting group title	D_15 QIV+0MF59

Reporting group description:

Subjects who received 2 doses of non adjuvanted quadravalent influenza vaccine (QIV - 15µg per antigen) on day 1 and day 29.

Reporting group title	Q_7.5 cTIV+0MF59

Reporting group description:

Subjects who received 2 doses of non adjuvanted trivalent influenza vaccine (cTIV - 7.5µg per antigen) on day 1 and day 29.

Reporting group title	E_7.5 aTIV+ ⅛MF59

Reporting group description:

Subjects who received 2 doses of ⅛ MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.

Reporting group title	F_7.5 aQIV+ ⅛MF59

Reporting group description:

Subjects who received 2 doses of ⅛MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.

Reporting group title	G_7.5 aTIV+ ¼MF59

Reporting group description:

Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.

Reporting group title	H_15 aTIV+¼MF59

Reporting group description:

Subjects who received 2 doses of ¼MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.

Reporting group title	I_7.5 aQIV+¼MF59

Reporting group description:

Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV – 7.5µg per antigen) on day 1 and day 29.

Reporting group title	J_15 aQIV+¼MF59
Reporting group description:	
Subjects who received 2 doses of ¼MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	K_7.5 aTIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	L_15 aTIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	M_7.5 aQIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 7.5µg per antigen) on day 1 and day 29.	
Reporting group title	N_15 aQIV+½MF59
Reporting group description:	
Subjects who received 2 doses of ½ MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1 and day 29.	
Reporting group title	O_15 aTIV+fullMF59
Reporting group description:	
Subjects who received one dose of full MF59 Dose adjuvanted trivalent influenza vaccine (aTIV - 15µg per antigen) on day 1.	
Reporting group title	P_15 aQIV+fullMF59
Reporting group description:	
Subjects who received one dose of full MF59 Dose adjuvanted quadravalent influenza vaccine (aQIV - 15µg per antigen) on day 1.	

Serious adverse events	A_7.5 TIV+0MF59	B_15 TIV+0MF59	C_7.5 QIV+0MF59
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Infections and infestations			
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	D_15 QIV+0MF59	Q_7.5 cTIV+0MF59	E_7.5 aTIV+ ⅛MF59
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 28 (3.57%)	1 / 26 (3.85%)	1 / 24 (4.17%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Infections and infestations			
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 28 (3.57%)	0 / 26 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	F_7.5 aQIV+ ⅛MF59	G_7.5 aTIV+ ¼MF59	H_15 aTIV+¼MF59
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Infections and infestations			
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	I_7.5 aQIV+¼MF59	J_15 aQIV+¼MF59	K_7.5 aTIV+½MF59
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	0 / 27 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from	0	0	0

adverse events			
Infections and infestations			
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	L_15 aTIV+½MF59	M_7.5 aQIV+½MF59	N_15 aQIV+½MF59

Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 23 (8.70%)	1 / 22 (4.55%)	1 / 25 (4.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Infections and infestations			
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	1 / 22 (4.55%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	O_15 aTIV+fullMF59	P_15 aQIV+fullMF59	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Infections and infestations			
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis rotavirus			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis bacterial			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	A_7.5 TIV+0MF59	B_15 TIV+0MF59	C_7.5 QIV+0MF59
Total subjects affected by non-serious adverse events			
subjects affected / exposed	23 / 25 (92.00%)	20 / 22 (90.91%)	25 / 25 (100.00%)
Nervous system disorders			
Somnolence			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 25 (24.00%)	6 / 22 (27.27%)	8 / 25 (32.00%)
occurrences (all)	14	14	14
General disorders and administration site conditions			
Chills			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 25 (8.00%)	2 / 22 (9.09%)	2 / 25 (8.00%)
occurrences (all)	6	2	2
Crying			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 25 (40.00%)	10 / 22 (45.45%)	5 / 25 (20.00%)
occurrences (all)	15	25	6
Injection site erythema			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	8 / 25 (32.00%)	8 / 22 (36.36%)	6 / 25 (24.00%)
occurrences (all)	11	10	9
Injection site haemorrhage			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	7 / 25 (28.00%)	5 / 22 (22.73%)	5 / 25 (20.00%)
occurrences (all)	10	8	5
Injection site induration			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 25 (12.00%)	2 / 22 (9.09%)	1 / 25 (4.00%)
occurrences (all)	3	2	1
Injection site pain			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 25 (20.00%)	8 / 22 (36.36%)	3 / 25 (12.00%)
occurrences (all)	8	8	3
Injection site swelling			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 25 (4.00%)	2 / 22 (9.09%)	0 / 25 (0.00%)
occurrences (all)	1	2	0
Irritability postvaccinal			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 25 (28.00%)	7 / 22 (31.82%)	9 / 25 (36.00%)
occurrences (all)	10	10	12
Gastrointestinal disorders			
Constipation			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 25 (4.00%)	1 / 22 (4.55%)	1 / 25 (4.00%)
occurrences (all)	1	1	1
Diarrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 25 (40.00%)	8 / 22 (36.36%)	10 / 25 (40.00%)
occurrences (all)	13	15	15
Gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Teething			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 25 (4.00%)	1 / 22 (4.55%)	1 / 25 (4.00%)
occurrences (all)	1	1	2
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 25 (20.00%)	5 / 22 (22.73%)	5 / 25 (20.00%)
occurrences (all)	8	5	5
Nasal congestion			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 22 (4.55%)	1 / 25 (4.00%)
occurrences (all)	0	1	1
Psychiatric disorders			
Eating disorder			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 25 (40.00%)	9 / 22 (40.91%)	7 / 25 (28.00%)
occurrences (all)	14	20	14
Insomnia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Irritability			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	9 / 25 (36.00%)	9 / 22 (40.91%)	10 / 25 (40.00%)
occurrences (all)	16	24	16
Infections and infestations			

Bronchitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 25 (4.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences (all)	1	0	1
Conjunctivitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Ear infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	3 / 22 (13.64%)	2 / 25 (8.00%)
occurrences (all)	0	3	4
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 25 (4.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences (all)	1	0	1
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 22 (4.55%)	2 / 25 (8.00%)
occurrences (all)	0	1	2
Nasopharyngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 25 (16.00%)	5 / 22 (22.73%)	5 / 25 (20.00%)
occurrences (all)	4	7	5
Otitis media			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 25 (4.00%)	2 / 22 (9.09%)	2 / 25 (8.00%)
occurrences (all)	1	2	2
Rhinitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 25 (16.00%)	4 / 22 (18.18%)	4 / 25 (16.00%)
occurrences (all)	6	4	4
Tonsillitis			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 25 (0.00%)	1 / 22 (4.55%)	1 / 25 (4.00%)
occurrences (all)	0	1	1
Upper respiratory tract infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 25 (16.00%)	4 / 22 (18.18%)	4 / 25 (16.00%)
occurrences (all)	5	5	4
Varicella			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	D_15 QIV+0MF59	Q_7.5 cTIV+0MF59	E_7.5 aTIV+ ⅛MF59
Total subjects affected by non-serious adverse events			
subjects affected / exposed	26 / 28 (92.86%)	22 / 26 (84.62%)	23 / 24 (95.83%)
Nervous system disorders			
Somnolence			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 28 (21.43%)	11 / 26 (42.31%)	10 / 24 (41.67%)
occurrences (all)	8	13	13
General disorders and administration site conditions			
Chills			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 28 (3.57%)	2 / 26 (7.69%)	4 / 24 (16.67%)
occurrences (all)	4	2	7
Crying			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	11 / 28 (39.29%)	8 / 26 (30.77%)	10 / 24 (41.67%)
occurrences (all)	23	9	20
Injection site erythema			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	9 / 28 (32.14%)	10 / 26 (38.46%)	8 / 24 (33.33%)
occurrences (all)	13	13	12
Injection site haemorrhage			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 28 (10.71%)	4 / 26 (15.38%)	4 / 24 (16.67%)
occurrences (all)	4	5	4
Injection site induration			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 28 (17.86%)	4 / 26 (15.38%)	4 / 24 (16.67%)
occurrences (all)	6	6	5
Injection site pain			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 28 (21.43%)	8 / 26 (30.77%)	7 / 24 (29.17%)
occurrences (all)	10	9	8
Injection site swelling			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 28 (3.57%)	0 / 26 (0.00%)	2 / 24 (8.33%)
occurrences (all)	2	0	2
Irritability postvaccinal			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	9 / 28 (32.14%)	7 / 26 (26.92%)	11 / 24 (45.83%)
occurrences (all)	9	9	16
Gastrointestinal disorders			
Constipation			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	10 / 28 (35.71%)	9 / 26 (34.62%)	11 / 24 (45.83%)
occurrences (all)	19	11	17
Gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Teething			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 28 (10.71%)	0 / 26 (0.00%)	3 / 24 (12.50%)
occurrences (all)	4	0	3
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 28 (14.29%)	8 / 26 (30.77%)	6 / 24 (25.00%)
occurrences (all)	6	9	6
Nasal congestion			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	1 / 26 (3.85%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Psychiatric disorders			
Eating disorder			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 28 (35.71%)	5 / 26 (19.23%)	7 / 24 (29.17%)
occurrences (all)	21	6	18
Insomnia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	2 / 26 (7.69%)	0 / 24 (0.00%)
occurrences (all)	0	2	0
Irritability			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	12 / 28 (42.86%)	10 / 26 (38.46%)	12 / 24 (50.00%)
occurrences (all)	24	11	29
Infections and infestations			
Bronchitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 28 (7.14%)	1 / 26 (3.85%)	1 / 24 (4.17%)
occurrences (all)	2	1	1
Conjunctivitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 28 (3.57%)	1 / 26 (3.85%)	3 / 24 (12.50%)
occurrences (all)	1	1	3
Ear infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 28 (7.14%)	1 / 26 (3.85%)	2 / 24 (8.33%)
occurrences (all)	3	1	2
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 28 (7.14%)	0 / 26 (0.00%)	4 / 24 (16.67%)
occurrences (all)	2	0	4
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Nasopharyngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 28 (10.71%)	3 / 26 (11.54%)	5 / 24 (20.83%)
occurrences (all)	3	4	5
Otitis media			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 28 (7.14%)	2 / 26 (7.69%)	2 / 24 (8.33%)
occurrences (all)	2	2	2
Rhinitis			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	4 / 28 (14.29%)	4 / 26 (15.38%)	2 / 24 (8.33%)
occurrences (all)	5	4	2
Tonsillitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Upper respiratory tract infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 28 (17.86%)	3 / 26 (11.54%)	5 / 24 (20.83%)
occurrences (all)	7	5	5
Varicella			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 28 (0.00%)	0 / 26 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 28 (3.57%)	2 / 26 (7.69%)	0 / 24 (0.00%)
occurrences (all)	1	4	0

Non-serious adverse events	F_7.5 aQIV+ ⅛MF59	G_7.5 aTIV+ ¼MF59	H_15 aTIV+¼MF59
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 23 (86.96%)	22 / 23 (95.65%)	19 / 21 (90.48%)
Nervous system disorders			
Somnolence			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 23 (43.48%)	3 / 23 (13.04%)	7 / 21 (33.33%)
occurrences (all)	19	5	12
General disorders and administration site conditions			
Chills			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 23 (8.70%)	4 / 23 (17.39%)	3 / 21 (14.29%)
occurrences (all)	3	4	4
Crying			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	6 / 23 (26.09%)	7 / 23 (30.43%)	5 / 21 (23.81%)
occurrences (all)	9	10	7
Injection site erythema			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	12 / 23 (52.17%)	11 / 23 (47.83%)	8 / 21 (38.10%)
occurrences (all)	15	14	10
Injection site haemorrhage			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 23 (17.39%)	2 / 23 (8.70%)	2 / 21 (9.52%)
occurrences (all)	4	2	2
Injection site induration			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 23 (26.09%)	4 / 23 (17.39%)	5 / 21 (23.81%)
occurrences (all)	6	4	6
Injection site pain			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 23 (30.43%)	5 / 23 (21.74%)	6 / 21 (28.57%)
occurrences (all)	10	6	8
Injection site swelling			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 23 (17.39%)	2 / 23 (8.70%)	4 / 21 (19.05%)
occurrences (all)	4	2	4
Irritability postvaccinal			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 23 (26.09%)	6 / 23 (26.09%)	4 / 21 (19.05%)
occurrences (all)	10	7	5
Gastrointestinal disorders			
Constipation			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 23 (43.48%)	6 / 23 (26.09%)	10 / 21 (47.62%)
occurrences (all)	19	6	19
Gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Teething			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 23 (8.70%)	1 / 23 (4.35%)	4 / 21 (19.05%)
occurrences (all)	3	1	5
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 23 (8.70%)	6 / 23 (26.09%)	4 / 21 (19.05%)
occurrences (all)	4	6	5
Nasal congestion			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Rhinorrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Eating disorder			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 23 (43.48%)	3 / 23 (13.04%)	8 / 21 (38.10%)
occurrences (all)	19	5	11
Insomnia			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 23 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Irritability			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 23 (43.48%)	7 / 23 (30.43%)	9 / 21 (42.86%)
occurrences (all)	20	10	17
Infections and infestations			
Bronchitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	1 / 23 (4.35%)	2 / 21 (9.52%)
occurrences (all)	0	1	2
Conjunctivitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 23 (0.00%)	2 / 21 (9.52%)
occurrences (all)	0	0	3
Ear infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	5 / 23 (21.74%)	1 / 21 (4.76%)
occurrences (all)	1	5	1
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 23 (13.04%)	1 / 23 (4.35%)	1 / 21 (4.76%)
occurrences (all)	3	1	1
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	1 / 23 (4.35%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Nasopharyngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	1 / 23 (4.35%)	4 / 21 (19.05%)
occurrences (all)	1	1	4
Otitis media			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	2 / 23 (8.70%)	1 / 23 (4.35%)	1 / 21 (4.76%)
occurrences (all)	2	1	1
Rhinitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 23 (13.04%)	3 / 23 (13.04%)	3 / 21 (14.29%)
occurrences (all)	3	3	3
Tonsillitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 23 (26.09%)	3 / 23 (13.04%)	7 / 21 (33.33%)
occurrences (all)	7	3	7
Varicella			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	2 / 23 (8.70%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	I_7.5 aQIV+¼MF59	J_15 aQIV+¼MF59	K_7.5 aTIV+½MF59
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 24 (83.33%)	24 / 24 (100.00%)	26 / 27 (96.30%)
Nervous system disorders			
Somnolence			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 24 (12.50%)	8 / 24 (33.33%)	9 / 27 (33.33%)
occurrences (all)	8	12	13
General disorders and administration site conditions			
Chills			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	2 / 24 (8.33%)	4 / 24 (16.67%)	2 / 27 (7.41%)
occurrences (all)	2	6	2
Crying			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 24 (20.83%)	11 / 24 (45.83%)	11 / 27 (40.74%)
occurrences (all)	8	22	20
Injection site erythema			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 24 (25.00%)	11 / 24 (45.83%)	9 / 27 (33.33%)
occurrences (all)	7	15	16
Injection site haemorrhage			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 24 (12.50%)	3 / 24 (12.50%)	6 / 27 (22.22%)
occurrences (all)	3	3	7
Injection site induration			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 24 (25.00%)	4 / 24 (16.67%)	6 / 27 (22.22%)
occurrences (all)	7	4	7
Injection site pain			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	8 / 24 (33.33%)	7 / 24 (29.17%)	12 / 27 (44.44%)
occurrences (all)	10	9	18
Injection site swelling			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 24 (12.50%)	5 / 24 (20.83%)	3 / 27 (11.11%)
occurrences (all)	3	5	4
Irritability postvaccinal			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 24 (8.33%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences (all)	2	0	0
Pyrexia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	12 / 24 (50.00%)	9 / 24 (37.50%)	9 / 27 (33.33%)
occurrences (all)	12	12	12

Gastrointestinal disorders			
Constipation			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 24 (16.67%)	7 / 24 (29.17%)	8 / 27 (29.63%)
occurrences (all)	6	13	15
Gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences (all)	0	0	0
Teething			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	2 / 24 (8.33%)	1 / 27 (3.70%)
occurrences (all)	0	3	1
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 24 (12.50%)	3 / 24 (12.50%)	7 / 27 (25.93%)
occurrences (all)	3	4	9
Nasal congestion			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	1 / 27 (3.70%)
occurrences (all)	0	1	1
Rhinorrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 24 (8.33%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences (all)	3	0	0
Psychiatric disorders			
Eating disorder			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 24 (20.83%)	7 / 24 (29.17%)	11 / 27 (40.74%)
occurrences (all)	10	9	13

Insomnia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences (all)	0	0	0
Irritability			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 24 (29.17%)	11 / 24 (45.83%)	11 / 27 (40.74%)
occurrences (all)	19	29	19
Infections and infestations			
Bronchitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	2 / 27 (7.41%)
occurrences (all)	0	1	2
Conjunctivitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	2 / 27 (7.41%)
occurrences (all)	0	1	2
Ear infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 24 (8.33%)	5 / 24 (20.83%)	3 / 27 (11.11%)
occurrences (all)	2	5	4
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 24 (8.33%)	1 / 24 (4.17%)	3 / 27 (11.11%)
occurrences (all)	2	1	3
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	1 / 27 (3.70%)
occurrences (all)	0	0	2
Nasopharyngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 24 (16.67%)	5 / 24 (20.83%)	3 / 27 (11.11%)
occurrences (all)	5	6	4
Otitis media			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	3 / 24 (12.50%)	2 / 24 (8.33%)	2 / 27 (7.41%)
occurrences (all)	4	3	2
Rhinitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 24 (4.17%)	4 / 24 (16.67%)	6 / 27 (22.22%)
occurrences (all)	1	5	6
Tonsillitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	0 / 24 (0.00%)	0 / 27 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 24 (20.83%)	4 / 24 (16.67%)	6 / 27 (22.22%)
occurrences (all)	5	4	7
Varicella			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 24 (8.33%)	0 / 24 (0.00%)	1 / 27 (3.70%)
occurrences (all)	2	0	1
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	1 / 27 (3.70%)
occurrences (all)	0	1	1

Non-serious adverse events	L_15 aTIV+½MF59	M_7.5 aQIV+½MF59	N_15 aQIV+½MF59
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 23 (91.30%)	21 / 22 (95.45%)	24 / 25 (96.00%)
Nervous system disorders			
Somnolence			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 23 (26.09%)	7 / 22 (31.82%)	8 / 25 (32.00%)
occurrences (all)	9	11	14
General disorders and administration site conditions			
Chills			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	3 / 23 (13.04%)	2 / 22 (9.09%)	1 / 25 (4.00%)
occurrences (all)	4	4	1
Crying			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	13 / 23 (56.52%)	11 / 22 (50.00%)	8 / 25 (32.00%)
occurrences (all)	28	15	16
Injection site erythema			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	10 / 23 (43.48%)	7 / 22 (31.82%)	13 / 25 (52.00%)
occurrences (all)	13	11	21
Injection site haemorrhage			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 23 (30.43%)	2 / 22 (9.09%)	2 / 25 (8.00%)
occurrences (all)	8	3	2
Injection site induration			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	8 / 23 (34.78%)	3 / 22 (13.64%)	6 / 25 (24.00%)
occurrences (all)	9	3	10
Injection site pain			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 23 (30.43%)	5 / 22 (22.73%)	9 / 25 (36.00%)
occurrences (all)	9	6	13
Injection site swelling			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 23 (17.39%)	0 / 22 (0.00%)	6 / 25 (24.00%)
occurrences (all)	6	0	9
Irritability postvaccinal			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 23 (30.43%)	10 / 22 (45.45%)	5 / 25 (20.00%)
occurrences (all)	13	13	12

Gastrointestinal disorders			
Constipation			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Diarrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	8 / 23 (34.78%)	10 / 22 (45.45%)	11 / 25 (44.00%)
occurrences (all)	12	14	14
Gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Teething			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	2 / 22 (9.09%)	2 / 25 (8.00%)
occurrences (all)	1	2	3
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	6 / 23 (26.09%)	4 / 22 (18.18%)	5 / 25 (20.00%)
occurrences (all)	6	5	6
Nasal congestion			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	2 / 22 (9.09%)	0 / 25 (0.00%)
occurrences (all)	0	2	0
Rhinorrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Eating disorder			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	11 / 23 (47.83%)	8 / 22 (36.36%)	8 / 25 (32.00%)
occurrences (all)	20	12	15

Insomnia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Irritability			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	13 / 23 (56.52%)	10 / 22 (45.45%)	12 / 25 (48.00%)
occurrences (all)	36	19	21
Infections and infestations			
Bronchitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 23 (8.70%)	3 / 22 (13.64%)	1 / 25 (4.00%)
occurrences (all)	2	3	1
Conjunctivitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Ear infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 23 (13.04%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences (all)	5	0	1
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	1 / 22 (4.55%)	2 / 25 (8.00%)
occurrences (all)	1	1	2
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	0 / 22 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	8 / 22 (36.36%)	4 / 25 (16.00%)
occurrences (all)	1	8	4
Otitis media			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	1 / 23 (4.35%)	1 / 22 (4.55%)	3 / 25 (12.00%)
occurrences (all)	1	2	4
Rhinitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 23 (13.04%)	3 / 22 (13.64%)	6 / 25 (24.00%)
occurrences (all)	3	3	7
Tonsillitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	5 / 23 (21.74%)	4 / 22 (18.18%)	8 / 25 (32.00%)
occurrences (all)	7	4	9
Varicella			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 23 (4.35%)	0 / 22 (0.00%)	2 / 25 (8.00%)
occurrences (all)	1	0	2
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 23 (0.00%)	0 / 22 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1

Non-serious adverse events	O_15 aTIV+fullMF59	P_15 aQIV+fullMF59	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 26 (80.77%)	21 / 22 (95.45%)	
Nervous system disorders			
Somnolence			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 26 (26.92%)	5 / 22 (22.73%)	
occurrences (all)	7	5	
General disorders and administration site conditions			
Chills			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 26 (0.00%)	1 / 22 (4.55%)		
occurrences (all)	0	1		
Crying				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	5 / 26 (19.23%)	6 / 22 (27.27%)		
occurrences (all)	5	7		
Injection site erythema				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	8 / 26 (30.77%)	3 / 22 (13.64%)		
occurrences (all)	8	4		
Injection site haemorrhage				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	1 / 26 (3.85%)	2 / 22 (9.09%)		
occurrences (all)	1	2		
Injection site induration				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	6 / 26 (23.08%)	2 / 22 (9.09%)		
occurrences (all)	6	3		
Injection site pain				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	7 / 26 (26.92%)	4 / 22 (18.18%)		
occurrences (all)	7	4		
Injection site swelling				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	0 / 26 (0.00%)	2 / 22 (9.09%)		
occurrences (all)	0	2		
Irritability postvaccinal				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)		
occurrences (all)	0	0		
Pyrexia				
alternative dictionary used: MedDRA 17.1				
subjects affected / exposed	6 / 26 (23.08%)	5 / 22 (22.73%)		
occurrences (all)	6	8		

Gastrointestinal disorders			
Constipation			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Diarrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	9 / 26 (34.62%)	6 / 22 (27.27%)	
occurrences (all)	14	7	
Gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Teething			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 26 (3.85%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 26 (3.85%)	5 / 22 (22.73%)	
occurrences (all)	1	5	
Nasal congestion			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Rhinorrhoea			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	2	
Psychiatric disorders			
Eating disorder			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 26 (11.54%)	5 / 22 (22.73%)	
occurrences (all)	4	8	

Insomnia			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Irritability			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	7 / 26 (26.92%)	6 / 22 (27.27%)	
occurrences (all)	8	6	
Infections and infestations			
Bronchitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Conjunctivitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Ear infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	3 / 26 (11.54%)	1 / 22 (4.55%)	
occurrences (all)	4	2	
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	1 / 26 (3.85%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Laryngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	2 / 26 (7.69%)	3 / 22 (13.64%)	
occurrences (all)	2	4	
Otitis media			
alternative dictionary used: MedDRA 17.1			

subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Rhinitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	4 / 26 (15.38%)	4 / 22 (18.18%)	
occurrences (all)	5	4	
Tonsillitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	8 / 26 (30.77%)	1 / 22 (4.55%)	
occurrences (all)	8	1	
Varicella			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	0 / 26 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None

Notes: